Bortezomib (PS-341)

Name: Bortezomib (PS-341)
Brand: Selleck Chemicals
SKU: S1013
Rating: 5 (682 reviews)

For research use only.

Catalog No.S1013 Synonyms: LDP-341, MLM341, NSC 681239

682 publications

CAS No. 179324-69-7

Bortezomib (PS-341, LDP-341, MLM341, NSC 681239) is a potent 20S proteasome inhibitor with K_i of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. Bortezomib (PS-341) inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.

Selleck's Bortezomib (PS-341) has been cited by 682 publications

Nature, 2021, 10.1038/s41586-020-03118-2

PubMed: 33442055 ( click the link to review the publication )

Science, 2020, eabd0811

PubMed: 33243852 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Stem Cell, 2020, 7;26(5):755-765 e7

PubMed: 32386556 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):371-386

PubMed: 32109374 ( click the link to review the publication )

Nature, 2019, 567(7747):262-266

PubMed: 30842662 ( click the link to review the publication )

Science, 2019, 363(6429)

PubMed: 30792274 ( click the link to review the publication )

Cell, 2019, 178(2):361-373

PubMed: 31204100 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 35(1):46-63

PubMed: 30581152 ( click the link to review the publication )

Nature, 2018, 560(7718):325-330

PubMed: 30089904 ( click the link to review the publication )

Nat Med, 2018, 24(4):497-504

PubMed: 29457796 ( click the link to review the publication )

Nat Med, 2018, 24(3):292-303

PubMed: 29400713 ( click the link to review the publication )

Nature, 2017, 550(7677):534-538

PubMed: 29045385 ( click the link to review the publication )

Science, 2017, eaal3755

PubMed: 28302793 ( click the link to review the publication )

Cell, 2017, 171(5):1094-1109

PubMed: 29149604 ( click the link to review the publication )

Nat Med, 2017, 23(9):1055-1062

PubMed: 28805822 ( click the link to review the publication )

Cancer Discov, 2017, 7(3):302-321

PubMed: 28108460 ( click the link to review the publication )

Cancer Cell, 2017, 32(6):748-760

PubMed: 29232553 ( click the link to review the publication )

Nat Med, 2014, 20(6):599-606

PubMed: 24813251 ( click the link to review the publication )

Cell Stem Cell, 2012, 11(2):242-52

PubMed: 22862949 ( click the link to review the publication )

Sci Adv, 2021, 7(3)eabc6364

PubMed: 33523898 ( click the link to review the publication )
Biomaterials, 2021, 271:120720

PubMed: 33639563 ( click the link to review the publication )

Theranostics, 2021, 11(5):2364-2380

PubMed: 33500730 ( click the link to review the publication )

Cell Death Dis, 2021, 12(1):52

PubMed: 33414430 ( click the link to review the publication )

FASEB J, 2021, 35(2):e21284

PubMed: 33484475 ( click the link to review the publication )

Sci Rep, 2021, 11(1):2074

PubMed: 33483574 ( click the link to review the publication )

Vascul Pharmacol, 2021, S1537-1891(21)00002-1

PubMed: 33422688 ( click the link to review the publication )

Cell Biol Int, 2021, 10.1002/cbin.11557

PubMed: 33501756 ( click the link to review the publication )

Biomedicines, 2021, 9(1)E33

PubMed: 33406639 ( click the link to review the publication )

JCI Insight, 2021, 141518

PubMed: 33476303 ( click the link to review the publication )

Viruses, 2021, 13(1)E83

PubMed: 33435377 ( click the link to review the publication )

Theranostics, 2021, 11(5):2364-2380

PubMed: 33500730 ( click the link to review the publication )

Oncol Rep, 2021, 45(4)34

PubMed: 33649855 ( click the link to review the publication )

Blood, 2020, 18 pii: blood

PubMed: 32187357 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(21):2001018

PubMed: 33173725 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(23):2001914

PubMed: 33304752 ( click the link to review the publication )

Mol Cell, 2020, 5;77(5):1092-1106 e9

PubMed: 31973889 ( click the link to review the publication )

Nat Commun, 2020, 22;11(1):1931

PubMed: 32321912 ( click the link to review the publication )

Autophagy, 2020, 10.1080/15548627.2020.1740529

PubMed: 32164484 ( click the link to review the publication )

Autophagy, 2020, 18;1-13

PubMed: 32186434 ( click the link to review the publication )

EMBO J, 2020, e105071

PubMed: 32840892 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.2853.2020

PubMed: 33310890 ( click the link to review the publication )

Leukemia, 2020, 10.1038/s41375-020-01034-y

PubMed: 32879426 ( click the link to review the publication )

Leukemia, 2020, 18

PubMed: 32424294 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 117(33):20004-20014

PubMed: 32747568 ( click the link to review the publication )
Clin Cancer Res, 2020, 27 pii: clincanres

PubMed: 32341033 ( click the link to review the publication )

Theranostics, 2020, 10(8):3366-3381

PubMed: 32206096 ( click the link to review the publication )

Blood Cancer J, 2020, 10(12):125

PubMed: 33318477 ( click the link to review the publication )

Cell Rep, 2020, 12;31(6):107632

PubMed: 32402277 ( click the link to review the publication )

Cell Rep, 2020, 3;30(9):2948-2962 e4

PubMed: 32130899 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038/s41418-020-00649-z

PubMed: 33110214 ( click the link to review the publication )

Redox Biol, 2020, 20;101465

PubMed: 32473993 ( click the link to review the publication )

Oncogene, 2020, 9

PubMed: 32388539 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1183-x

PubMed: 32034308 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 10.1007/s00018-020-03568-x

PubMed: 32607595 ( click the link to review the publication )

Sci Signal, 2020, 13(649)eaba5665

PubMed: 32934076 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 9;39(1):105

PubMed: 32517809 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3335

PubMed: 33187254 ( click the link to review the publication )

Cancers (Basel), 2020, 30;12(4):831

PubMed: 32235588 ( click the link to review the publication )

Cancers (Basel), 2020, 12(3)

PubMed: 32235770 ( click the link to review the publication )

Cancers (Basel), 2020, 11;12(5):E1207

PubMed: 32403415 ( click the link to review the publication )

PLoS Pathog, 2020, 16;16(3):e1008341

PubMed: 32176725 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):796

PubMed: 32968046 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):701

PubMed: 32839432 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):783

PubMed: 32951004 ( click the link to review the publication )

J Clin Med, 2020, 9(2)

PubMed: 32085480 ( click the link to review the publication )

Cells, 2020, 9(11)E2357

PubMed: 33114738 ( click the link to review the publication )

FASEB J, 2020, 34(9):12379-12391

PubMed: 32960474 ( click the link to review the publication )

Cell Chem Biol, 2020, 18 pii: S2451-9456(20)30117-3

PubMed: 32386596 ( click the link to review the publication )
Pain, 2020, 161(1):177-184

PubMed: 31490328 ( click the link to review the publication )

Front Immunol, 2020,

PubMed: 32903557 ( click the link to review the publication )

Oncoimmunology, 2020, 9(1):1831153

PubMed: 33110706 ( click the link to review the publication )

Curr Biol, 2020, S0960-9822(20)31156-8

PubMed: 32857970 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12853

PubMed: 33188726 ( click the link to review the publication )

Clin Sci (Lond), 2020, CS20201038

PubMed: 33289516 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:44

PubMed: 32117974 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:605989

PubMed: 33392195 ( click the link to review the publication )

Aging (Albany NY), 2020, 16;12(8):6611-6629

PubMed: 32298237 ( click the link to review the publication )

Respirology, 2020, 10.1111/resp.13867

PubMed: 32512637 ( click the link to review the publication )

Cancer Sci, 2020, 111(4):1279-1290

PubMed: 32058648 ( click the link to review the publication )

J Immunol, 2020, 205(10):2583-2594

PubMed: 33067378 ( click the link to review the publication )

FEBS J, 2020, 10.1111/febs.15675

PubMed: 33340237 ( click the link to review the publication )

Antioxidants (Basel), 2020, 9(12)E1300

PubMed: 33353055 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:117

PubMed: 32117764 ( click the link to review the publication )

J Cell Sci, 2020, jcs.241356

PubMed: 32546533 ( click the link to review the publication )

J Virol, 2020, 6;94(2) pii: e01173-19

PubMed: 31619561 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(9):5260-5273

PubMed: 32227582 ( click the link to review the publication )

Biochem Pharmacol, 2020, S0006-2952(20)30604-3

PubMed: 33333074 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(21)E7905

PubMed: 33114380 ( click the link to review the publication )

Sci Rep, 2020, 27;10(1):5562

PubMed: 32221318 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.015398

PubMed: 33082144 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 10.1038/s41401-020-00544-w

PubMed: 33139838 ( click the link to review the publication )
Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Mol Cell Biol, 2020, MCB.00269-20

PubMed: 33168699 ( click the link to review the publication )

Cell Cycle, 2020, 19;1-12

PubMed: 32423265 ( click the link to review the publication )

Int J Biochem Cell Biol, 2020, 122:105734

PubMed: 32119989 ( click the link to review the publication )

Toxicol In Vitro, 2020, 104928

PubMed: 32622998 ( click the link to review the publication )

Mol Cells, 2020, 31;43(1):23-33

PubMed: 31870133 ( click the link to review the publication )

Eur J Pharmacol, 2020, 875:173050

PubMed: 32142770 ( click the link to review the publication )

Int J Mol Med, 2020, 45(6):1661-1672

PubMed: 32236619 ( click the link to review the publication )

Saudi J Biol Sci, 2020, 27(8):2157-2163

PubMed: 32714042 ( click the link to review the publication )

PLoS One, 2020, 15(6):e0232068

PubMed: 32559187 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 8;521(2):414-419

PubMed: 31672277 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

SLAS Discov, 2020, 19;2472555220915851

PubMed: 32425084 ( click the link to review the publication )

Cell Biol Int, 2020, 10.1002/cbin.11322

PubMed: 32068318 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(6):4849-4856

PubMed: 32424523 ( click the link to review the publication )

Technol Cancer Res Treat, 2020, 19:1533033820948060

PubMed: 32924793 ( click the link to review the publication )

Turk J Haematol, 2020, 37(3):167-176

PubMed: 32160736 ( click the link to review the publication )

Hematology, 2020, 25(1):424-432

PubMed: 33191863 ( click the link to review the publication )

Haematologica, 2020, 10.3324/haematol.2019.227215

PubMed: 31919082 ( click the link to review the publication )

Clin Cancer Res, 2020, clincanres.1232.2020

PubMed: 32669378 ( click the link to review the publication )

EMBO Mol Med, 2020, e11793

PubMed: 32720440 ( click the link to review the publication )

Cancer Rep (Hoboken), 2020, e1267

PubMed: 32706923 ( click the link to review the publication )
Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Oncotarget, 2020, 11(7):727-739

PubMed: 32133047 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):89

PubMed: 32653014 ( click the link to review the publication )

RNA Biol, 2020, 10.1080/15476286.2020.1813439

PubMed: 32819190 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01408-7

PubMed: 32733069 ( click the link to review the publication )

Genes Chromosomes Cancer, 2020, 10.1002/gcc.22884

PubMed: 32614991 ( click the link to review the publication )

Br J Cancer, 2020, 10.1038/s41416-020-01191-y

PubMed: 33250513 ( click the link to review the publication )

Mol Cells, 2020, 43(11):935-944

PubMed: 33168788 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2020, 48(1):735-745

PubMed: 32272856 ( click the link to review the publication )

Mol Oncol, 2020, 10.1002/1878-0261.12853

PubMed: 33188726 ( click the link to review the publication )

J Leukoc Biol, 2020, 107(1):105-112

PubMed: 31729784 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202009137

PubMed: 32788348 ( click the link to review the publication )

Cancer Lett, 2020, 475:99-108

PubMed: 32014459 ( click the link to review the publication )

Nat Metab, 2020, 10.1038/s42255-020-0252-3

PubMed: 32778834 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9):E2341

PubMed: 32825035 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Autophagy, 2020, 1-17

PubMed: 32762399 ( click the link to review the publication )

J Virol, 2020, JVI.01604-20

PubMed: 32817219 ( click the link to review the publication )

Cell Rep, 2020, 32(2):107897

PubMed: 32668248 ( click the link to review the publication )

Hematology, 2020, 25(1):424-432

PubMed: 33191863 ( click the link to review the publication )

FEBS J, 2020, 10.1111/febs.15480

PubMed: 32648994 ( click the link to review the publication )

Oncotarget, 2020, 11(44):3984-3997

PubMed: 33216827 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32102381 ( click the link to review the publication )
Gastroenterology, 2019, 157(6):1615-1629

PubMed: 31446059 ( click the link to review the publication )

Hepatology, 2019, 10.1002/hep.31059

PubMed: 31808574 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):273

PubMed: 30655516 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4184

PubMed: 31519875 ( click the link to review the publication )

Sci Adv, 2019, 5(2):eaau7130

PubMed: 30775435 ( click the link to review the publication )

Autophagy, 2019, 15(11):1954-1969

PubMed: 30894069 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1635380

PubMed: 31242129 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(10):e9930

PubMed: 31476112 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0525-6

PubMed: 31358854 ( click the link to review the publication )

Leukemia, 2019, 33(1):171-180

PubMed: 30026574 ( click the link to review the publication )

Dev Cell, 2019, 50(1):11-24.e10

PubMed: 31130353 ( click the link to review the publication )

Dev Cell, 2019, 50(6):690-703.e6

PubMed: 31378590 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(6):2200-2209

PubMed: 30674681 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31138526 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31484670 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.212266

PubMed: 31101754 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):28

PubMed: 30717817 ( click the link to review the publication )

Kidney Int, 2019, 95(3):611-623

PubMed: 30685098 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31142515 ( click the link to review the publication )

Cancer Res, 2019, 79(21):5536-5549

PubMed: 31530568 ( click the link to review the publication )

Cell Rep, 2019, 27(6):1657-1665

PubMed: 31067453 ( click the link to review the publication )

Cell Rep, 2019, 29(5):1249-1260

PubMed: 31665637 ( click the link to review the publication )

J Control Release, 2019, 306:149-164

PubMed: 31121280 ( click the link to review the publication )
Elife, 2019,

PubMed: 31741433 ( click the link to review the publication )

Elife, 2019, 8e44161

PubMed: 30860482 ( click the link to review the publication )

Elife, 2019, 8e48469

PubMed: 31516121 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.45457

PubMed: 30907729 ( click the link to review the publication )

Haematologica, 2019, 103324/haematol2019216986

PubMed: 31123029 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32615

PubMed: 31390487 ( click the link to review the publication )

Oncogene, 2019, 38(16):3047-3060

PubMed: 30617306 ( click the link to review the publication )

mBio, 2019, 10(2)e00668-19

PubMed: 31015330 ( click the link to review the publication )

mBio, 2019, 10(3)

PubMed: 31088925 ( click the link to review the publication )

Am J Transplant, 2019, 19(3):724-736

PubMed: 30102844 ( click the link to review the publication )

Cancer Lett, 2019, 442:233-241

PubMed: 30419344 ( click the link to review the publication )

J Med Chem, 2019, 62(15):7042-7057

PubMed: 31271281 ( click the link to review the publication )

Cancers (Basel), 2019, 11(7)

PubMed: 31315220 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31756922 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)E85

PubMed: 30646520 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)E236

PubMed: 30781685 ( click the link to review the publication )

Cancers (Basel), 2019,

PubMed: 31466401 ( click the link to review the publication )

Cancers (Basel), 2019, 11(12)

PubMed: 31771104 ( click the link to review the publication )

PLoS Pathog, 2019, 15(1):e1007498

PubMed: 30645648 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):324

PubMed: 30975979 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):781

PubMed: 31611552 ( click the link to review the publication )

Cell Death Discov, 2019, 5:131

PubMed: 31482012 ( click the link to review the publication )

Cell Death Dis, 2019, 10(5):342

PubMed: 31019203 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.06.006

PubMed: 31303577 ( click the link to review the publication )
Cell Chem Biol, 2019, 26(11):1544-1558.e6

PubMed: 31522999 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(3):340-351

PubMed: 30612952 ( click the link to review the publication )

Cell Physiol Biochem, 2019, 53(6):999-1014

PubMed: 31838790 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(7):1205-1216

PubMed: 31092565 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-18-1319

PubMed: 31594826 ( click the link to review the publication )

Hum Mutat, 2019, 40(4):392-403

PubMed: 30609140 ( click the link to review the publication )

Mol Oncol, 2019, 13(2):290-306

PubMed: 30422399 ( click the link to review the publication )

Aging (Albany NY), 2019, 11(11):3624-3638

PubMed: 31170093 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(3):1653-1664

PubMed: 29916141 ( click the link to review the publication )

Neoplasia, 2019, 21(7):653-664

PubMed: 31132676 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:1659468

PubMed: 31281566 ( click the link to review the publication )

ACS Infect Dis, 2019, 5(12):2105-2117

PubMed: 31644867 ( click the link to review the publication )

Eur J Med Chem, 2019, 166:65-74

PubMed: 30684871 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(8):1622-1634

PubMed: 31497346 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2019, 1866(10):1544-1555

PubMed: 31326539 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2019, 1866(2):252-263

PubMed: 30445147 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786

PubMed: 31540997 ( click the link to review the publication )

ACS Chem Biol, 2019, 10.1021/acschembio-00191

PubMed: 31243962 ( click the link to review the publication )

J Immunol, 2019, 202(10):2849-2855

PubMed: 30936292 ( click the link to review the publication )

Mol Cancer Res, 2019,

PubMed: 31409628 ( click the link to review the publication )

Front Oncol, 2019, 9:958

PubMed: 31632904 ( click the link to review the publication )

Front Oncol, 2019, 9:722

PubMed: 31440466 ( click the link to review the publication )

J Cell Mol Med, 2019, 23(8):5390-5402

PubMed: 31140729 ( click the link to review the publication )
Mol Biol Cell, 2019, 30(7):838-850

PubMed: 30865564 ( click the link to review the publication )

Arthritis Res Ther, 2019, 21(1):50

PubMed: 30728075 ( click the link to review the publication )

Antimicrob Agents Chemother, 2019, 63(9)

PubMed: 31307977 ( click the link to review the publication )

Talanta, 2019, 199:32-39

PubMed: 30952265 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(20)

PubMed: 31635163 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(3)

PubMed: 30736330 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(24)

PubMed: 31817163 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7901

PubMed: 31133683 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):2443

PubMed: 30792442 ( click the link to review the publication )

Sci Rep, 2019, 9(1):6915

PubMed: 31061434 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7779

PubMed: 31123282 ( click the link to review the publication )

Sci Rep, 2019, 9(1):14394

PubMed: 31591429 ( click the link to review the publication )

Sci Rep, 2019, 9(1):18409

PubMed: 31804603 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7199

PubMed: 31076590 ( click the link to review the publication )

Sci Rep, 2019, 9(1):18062

PubMed: 31792264 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

J Biol Chem, 2019, 294(40):14562-14573

PubMed: 31371451 ( click the link to review the publication )

J Biol Chem, 2019,

PubMed: 30523157 ( click the link to review the publication )

Food Chem Toxicol, 2019, 131:110537

PubMed: 31150782 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Gene, 2019, 707:86-92

PubMed: 31071385 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:8711-8720

PubMed: 31576173 ( click the link to review the publication )

Cancer Commun (Lond), 2019, 39(1):81

PubMed: 31796105 ( click the link to review the publication )
Int J Oncol, 2019, 55(2):499-512

PubMed: 31268156 ( click the link to review the publication )

Cell Signal, 2019, 59:76-84

PubMed: 30878517 ( click the link to review the publication )

Cell Signal, 2019, 62:109351

PubMed: 31260799 ( click the link to review the publication )

J Cell Biochem, 2019, 120(3):3243-3258

PubMed: 30362618 ( click the link to review the publication )

Am J Transl Res, 2019, 11(7):4139-4150

PubMed: 31396324 ( click the link to review the publication )

Biochimie, 2019, 162:46-54

PubMed: 30946948 ( click the link to review the publication )

Molecules, 2019, 24(5)

PubMed: 30818834 ( click the link to review the publication )

Oncol Rep, 2019, 42(1):35-42

PubMed: 31115546 ( click the link to review the publication )

Oncol Rep, 2019, 41(3):1678-1690

PubMed: 30664164 ( click the link to review the publication )

ChemMedChem, 2019, 14(23):2005-2022

PubMed: 31675179 ( click the link to review the publication )

PLoS One, 2019, 14(11):e0225145

PubMed: 31703099 ( click the link to review the publication )

PLoS One, 2019, 14(12):e0225977

PubMed: 31826021 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 514(4):1140-1146

PubMed: 31103265 ( click the link to review the publication )

Onco Targets Ther, 2019, 12:11383-11391

PubMed: 31920329 ( click the link to review the publication )

Leuk Lymphoma, 2019, 10.1080/10428194.2019.1616190

PubMed: 31111763 ( click the link to review the publication )

Leuk Res, 2019, 78:3-11

PubMed: 30641417 ( click the link to review the publication )

Leuk Res, 2019, 78:12-20

PubMed: 30660961 ( click the link to review the publication )

Naunyn Schmiedebergs Arch Pharmacol, 2019, 392(4):461-466

PubMed: 30554340 ( click the link to review the publication )

Methods Enzymol, 2019, 619:145-159

PubMed: 30910019 ( click the link to review the publication )

Iran J Pharm Res, 2019, 18(Suppl1):119-131

PubMed: 32802093 ( click the link to review the publication )

Cell Rep, 2019, 28(12):3167-3181.e6

PubMed: 31533039 ( click the link to review the publication )

J Blood Med, 2019, 10:105-109

PubMed: 31043801 ( click the link to review the publication )

Oncotarget, 2019, 10(28):2709-2721

PubMed: 31105871 ( click the link to review the publication )

Oncotarget, 2019, 10(63):6781-6790

PubMed: 31827721 ( click the link to review the publication )
Toxicol Forensic Med, 2019, 4(1):13-17

PubMed: 32149269 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2019, 1863(6):1108-1115

PubMed: 30974160 ( click the link to review the publication )

Blood Adv, 2019, 3(1):51-62

PubMed: 30617217 ( click the link to review the publication )

Mol Cell, 2018, 70(5):906-919

PubMed: 29804830 ( click the link to review the publication )

Mol Cell, 2018, 72(5):862-874

PubMed: 30318442 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2877-2893

PubMed: 29863498 ( click the link to review the publication )

J Clin Invest, 2018, 128(10):4682-4696

PubMed: 30198908 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):387-401

PubMed: 29200404 ( click the link to review the publication )

Nat Commun, 2018, 9(1):502

PubMed: 29402884 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4514

PubMed: 30375513 ( click the link to review the publication )

Nat Commun, 2018, 9(1):672

PubMed: 29445180 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Autophagy, 2018, 14(6):958-971

PubMed: 29561705 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(24):6408-6420

PubMed: 30126942 ( click the link to review the publication )

Leukemia, 2018, 32(1):139-148

PubMed: 28663576 ( click the link to review the publication )

Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Theranostics, 2018, 8(9):2348-2360

PubMed: 29721084 ( click the link to review the publication )

Kidney Int, 2018, 93(3):670-680

PubMed: 29229189 ( click the link to review the publication )

Blood Cancer J, 2018, 8(11):105

PubMed: 30409995 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2018, 10(26):21825-21835

PubMed: 29897225 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):29

PubMed: 29482577 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):112

PubMed: 30180865 ( click the link to review the publication )

Oncogene, 2018, 37(33):4581-4598

PubMed: 29748621 ( click the link to review the publication )

Oncogene, 2018, 37(38):5221-5232

PubMed: 29849118 ( click the link to review the publication )
Oncogene, 2018, 37(3):363-376

PubMed: 28945225 ( click the link to review the publication )

Cancer Lett, 2018, 420:156-167

PubMed: 29410067 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

J Cereb Blood Flow Metab, 2018, 38(11):1924-1939

PubMed: 29972341 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):162

PubMed: 29415982 ( click the link to review the publication )

PLoS Genet, 2018, 14(1):e1007165

PubMed: 29370161 ( click the link to review the publication )

Oncoimmunology, 2018, 7(10):e1484981

PubMed: 30288346 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):1871-1880

PubMed: 29959200 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1416-1429

PubMed: 29703842 ( click the link to review the publication )

J Mol Cell Cardiol, 2018, 116:16-28

PubMed: 29371135 ( click the link to review the publication )

Mol Oncol, 2018, 12(12):2124-2135

PubMed: 30259640 ( click the link to review the publication )

Oncogenesis, 2018, 7(9):75

PubMed: 30250021 ( click the link to review the publication )

J Cell Physiol, 2018, 233(5):4258-4271

PubMed: 29057477 ( click the link to review the publication )

J Cell Sci, 2018, 131(14)jcs216671

PubMed: 29930081 ( click the link to review the publication )

Lab Invest, 2018, 98(6):708-714

PubMed: 29540860 ( click the link to review the publication )

Biochem Pharmacol, 2018, 156:291-301

PubMed: 30149015 ( click the link to review the publication )

Sci Rep, 2018, 8(1):671

PubMed: 29330435 ( click the link to review the publication )

J Biol Chem, 2018, 293(4):1178-1191

PubMed: 29183995 ( click the link to review the publication )

J Biol Chem, 2018, 293(7):2452-2465

PubMed: 29279332 ( click the link to review the publication )

Mar Drugs, 2018, 16(12)

PubMed: 30572618 ( click the link to review the publication )

J Ethnopharmacol, 2018, 220:220-227

PubMed: 29097252 ( click the link to review the publication )

Exp Cell Res, 2018, 371(2):353-363

PubMed: 30149001 ( click the link to review the publication )

Exp Cell Res, 2018, 369(1):120-128

PubMed: 29772221 ( click the link to review the publication )

J Mol Endocrinol, 2018, 60(2):45-54

PubMed: 29191827 ( click the link to review the publication )
BMC Cancer, 2018, 18(1):432

PubMed: 29661248 ( click the link to review the publication )

Int Immunopharmacol, 2018, 54:39-45

PubMed: 29100036 ( click the link to review the publication )

Molecules, 2018, 23(12)

PubMed: 30567313 ( click the link to review the publication )

Mol Cells, 2018, 41(12):1008-1015

PubMed: 30396235 ( click the link to review the publication )

Oncol Rep, 2018, 39(6):2873-2880

PubMed: 29693175 ( click the link to review the publication )

Oncol Rep, 2018, 40(6):3714-3724

PubMed: 30272343 ( click the link to review the publication )

Eur J Pharmacol, 2018, 830:17-25

PubMed: 29680228 ( click the link to review the publication )

Oncol Res, 2018, 26(3):421-429

PubMed: 28899456 ( click the link to review the publication )

Biosci Rep, 2018, 38(5)

PubMed: 30177525 ( click the link to review the publication )

Dis Markers, 2018, 2018:3810108

PubMed: 30647797 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 501(1):286-292

PubMed: 29729272 ( click the link to review the publication )

G3 (Bethesda), 2018, 8(7):2193-2204

PubMed: 29735526 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 505(1):126-133

PubMed: 30236985 ( click the link to review the publication )

J Bone Miner Metab, 2018, 36(5):537-546

PubMed: 29027021 ( click the link to review the publication )

Ann Diagn Pathol, 2018, 32:28-34

PubMed: 29414394 ( click the link to review the publication )

Target Oncol, 2018, 13(6):779-793

PubMed: 30446871 ( click the link to review the publication )

J Exp Med, 2018, 215(5):1301-1313

PubMed: 29703731 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29423101 ( click the link to review the publication )

Oncotarget, 2018, 9(23):16521-16532

PubMed: 29662664 ( click the link to review the publication )

Viruses, 2018, 10(10)

PubMed: 30261679 ( click the link to review the publication )

Oncotarget, 2018, 9(5):6450-6462

PubMed: 29464084 ( click the link to review the publication )

Leuk Res, 2018, 64:34-41

PubMed: 29175379 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29861856 ( click the link to review the publication )
J Mol Cell Cardiol, 2018, 116:16-28

PubMed: 29371135 ( click the link to review the publication )

Blood, 2017, 5;129(1):88-99

PubMed: 27784673 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1692

PubMed: 29167449 ( click the link to review the publication )

Nat Commun, 2017, 8:15244

PubMed: 28489076 ( click the link to review the publication )

Nat Commun, 2017, 8:15676

PubMed: 28607490 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1391

PubMed: 29123089 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(4):1012-1024

PubMed: 28151717 ( click the link to review the publication )

Leukemia, 2017, 31(7):1570-1581

PubMed: 27890927 ( click the link to review the publication )

Cancer Immunol Res, 2017, 5(10):839-846

PubMed: 28903971 ( click the link to review the publication )

Cancer Res, 2017, 77(22):6282-6298

PubMed: 28978635 ( click the link to review the publication )

Cancer Res, 2017, 77(11):2927-2937

PubMed: 28404587 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3084-3096

PubMed: 27993968 ( click the link to review the publication )

Cell Mol Immunol, 2017, 10.1038/cmi.2017.8

PubMed: 28690324 ( click the link to review the publication )

Genomics Inform, 2017, 15(3):87-97

PubMed: 29020724 ( click the link to review the publication )

Cancer Lett, 2017, 405:63-72

PubMed: 28716527 ( click the link to review the publication )

J Pathol, 2017, 241(4):534-546

PubMed: 27976373 ( click the link to review the publication )

Cell Death Dis, 2017, 8(2):e2585

PubMed: 28151478 ( click the link to review the publication )

Exp Mol Med, 2017, 49(8):e365

PubMed: 28798402 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 28108597 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(11):2375-2386

PubMed: 28878026 ( click the link to review the publication )

Br J Haematol, 2017, 179(5):756-771

PubMed: 29048129 ( click the link to review the publication )

J Cancer, 2017, 8(5):839-851

PubMed: 28382147 ( click the link to review the publication )

Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

J Virol, 2017, 91(12)e00554-17

PubMed: 28404849 ( click the link to review the publication )
Biochem Pharmacol, 2017, 143:118-128

PubMed: 28642038 ( click the link to review the publication )

Sci Rep, 2017, 7(1):5423

PubMed: 28710427 ( click the link to review the publication )

Sci Rep, 2017, 7:44700

PubMed: 28304377 ( click the link to review the publication )

Am J Pathol, 2017, 187(12):2775-2787

PubMed: 28919113 ( click the link to review the publication )

J Biol Chem, 2017, 292(28):11970-11979

PubMed: 28588027 ( click the link to review the publication )

J Biol Chem, 2017, 292(30):12542

PubMed: 28754767 ( click the link to review the publication )

Endocrinology, 2017, 158(4):1005-1014

PubMed: 28323983 ( click the link to review the publication )

Endocrinology, 2017, 158(10):3097-3108

PubMed: 28938421 ( click the link to review the publication )

Biomed Pharmacother, 2017, 88:562-568

PubMed: 28131096 ( click the link to review the publication )

BMC Genomics, 2017, 18(1):127

PubMed: 28166733 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(1):20-34

PubMed: 28760737 ( click the link to review the publication )

Cell Signal, 2017, 32:124-132

PubMed: 28161489 ( click the link to review the publication )

Mol Brain, 2017, 10(1):7

PubMed: 28196470 ( click the link to review the publication )

Life Sci, 2017, 173:36-42

PubMed: 28212825 ( click the link to review the publication )

BMC Cancer, 2017, 17(1):366

PubMed: 28545541 ( click the link to review the publication )

Neurotox Res, 2017, 32(4):555-562

PubMed: 28612296 ( click the link to review the publication )

Transl Oncol, 2017, 10(4):632-640

PubMed: 28668761 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 488(2):400-406

PubMed: 28502636 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(12):2916-2925

PubMed: 28509582 ( click the link to review the publication )

Cancer Genomics Proteomics, 2017, 14(1):35-51

PubMed: 28031236 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):494-506

PubMed: 28346091 ( click the link to review the publication )

Oncol Lett, 2017, 13(2):647-654

PubMed: 28356941 ( click the link to review the publication )

Cancer Metab, 2017, 5:7

PubMed: 28855983 ( click the link to review the publication )

Oncotarget, 2017, 8(34):57047-57057

PubMed: 28915653 ( click the link to review the publication )
Oncotarget, 2017, 8(70):114698-114709

PubMed: 29383113 ( click the link to review the publication )

Oncotarget, 2017, 9(3):2984-3000

PubMed: 29423023 ( click the link to review the publication )

Cell, 2017, 170(5):860-874

PubMed: 28803730 ( click the link to review the publication )

Oncotarget, 2017, 8(70):114698-114709

PubMed: 29383113 ( click the link to review the publication )

Oncotarget, 2017, 8(46):80109-80123

PubMed: 29113288 ( click the link to review the publication )

Cell, 2017, 169(6):1105-1118

PubMed: 28575672 ( click the link to review the publication )

Cell Mol Immunol, 2017, 10.1038/cmi.2017.8

PubMed: 28690324 ( click the link to review the publication )

Hepatology, 2017, 66(3):855-868

PubMed: 28439950 ( click the link to review the publication )

Sci Rep, 2017, 7(1):682

PubMed: 28386133 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56243-56254

PubMed: 28915587 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52445-52456

PubMed: 28881742 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(2):202-12

PubMed: 26655835 ( click the link to review the publication )

Sci Transl Med, 2016, 8(339):339ra70

PubMed: 27194728 ( click the link to review the publication )

Hepatology, 2016, 64(1):161-74

PubMed: 26926206 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:12368

PubMed: 27492902 ( click the link to review the publication )

Nat Commun, 2016, 7:13150

PubMed: 27748395 ( click the link to review the publication )

Autophagy, 2016, 12(4):632-47

PubMed: 27050454 ( click the link to review the publication )

EMBO J, 2016, 35(23):2602-2613

PubMed: 27789522 ( click the link to review the publication )

Dev Cell, 2016, 37(1):15-33

PubMed: 27052834 ( click the link to review the publication )

Leukemia, 2016, 30(4):861-72

PubMed: 26658839 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(32):9015-20

PubMed: 27450084 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(46):13162-13167

PubMed: 27799547 ( click the link to review the publication )

Genes Dev, 2016, 30(24):2684-2695

PubMed: 28087713 ( click the link to review the publication )
Cancer Res, 2016, 76(12):3531-40

PubMed: 27197154 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(5):1222-33

PubMed: 26527748 ( click the link to review the publication )

Plant Cell, 2016, 28(6):1279-96

PubMed: 27194708 ( click the link to review the publication )

Matrix Biol, 2016, 55:22-34

PubMed: 27016342 ( click the link to review the publication )

Blood Cancer J, 2016, 6(8):e462

PubMed: 27564460 ( click the link to review the publication )

Blood Cancer J, 2016, 6(7):e446

PubMed: 27421095 ( click the link to review the publication )

Cell Rep, 2016, 16(1):120-132

PubMed: 27320908 ( click the link to review the publication )

Oncogene, 2016, 35(38):4973-80

PubMed: 26973240 ( click the link to review the publication )

Cancer Lett, 2016, 372(1):82-8

PubMed: 26721204 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

PLoS Pathog, 2016, 12(10):e1005929

PubMed: 27706223 ( click the link to review the publication )

Lab Chip, 2016, 16(2):334-44

PubMed: 26660268 ( click the link to review the publication )

J Neurosci, 2016, 36(6):1930-41

PubMed: 26865616 ( click the link to review the publication )

Cell Death Dis, 2016, 7(12):e2492

PubMed: 27906188 ( click the link to review the publication )

FASEB J, 2016, 30(2):923-32

PubMed: 26546130 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(8):1075-81

PubMed: 27087021 ( click the link to review the publication )

Br J Haematol, 2016, 173(1):70-81

PubMed: 26729247 ( click the link to review the publication )

Dis Model Mech, 2016, 9(11):1317-1328

PubMed: 27519691 ( click the link to review the publication )

Mol Biol Cell, 2016, 27(8):1272-85

PubMed: 26941331 ( click the link to review the publication )

Am J Pathol, 2016, 186(3):678-90

PubMed: 26801735 ( click the link to review the publication )

J Biol Chem, 2016, 291(45):23719-23733

PubMed: 27621311 ( click the link to review the publication )

J Biol Chem, 2016, 291(2):939-47

PubMed: 26527686 ( click the link to review the publication )

J Biol Chem, 2016, 291(29):15082-92

PubMed: 27226596 ( click the link to review the publication )

Int J Oncol, 2016, 49(5):1848-1858

PubMed: 27601063 ( click the link to review the publication )
Cancer Biol Ther, 2016, 17(9):966-75

PubMed: 27434731 ( click the link to review the publication )

Eur J Pharmacol, 2016, 791:99-104

PubMed: 27568836 ( click the link to review the publication )

Eur J Cell Biol, 2016, 95(10):389-400

PubMed: 27567537 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0150044

PubMed: 26982031 ( click the link to review the publication )

PLoS One, 2016, 11(12):e0168193

PubMed: 27978543 ( click the link to review the publication )

PLoS One, 2016, 11(3):e0150484

PubMed: 26930278 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(7):1677-86

PubMed: 26421357 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(6):783-798

PubMed: 27250763 ( click the link to review the publication )

Cancer Biol Ther, 2016, 17(5):546-57

PubMed: 27029345 ( click the link to review the publication )

Oncotarget, 2016, 7(11):12254-66

PubMed: 26930721 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77622-77634

PubMed: 27769058 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4559-69

PubMed: 26683226 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(3):1161-78

PubMed: 26578593 ( click the link to review the publication )

Oncotarget, 2016, 7(25):38523-38538

PubMed: 27229530 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4062-76

PubMed: 26716651 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2016, 95(2):751-60

PubMed: 27045812 ( click the link to review the publication )

Sarcoma, 2016, 2016:3484673

PubMed: 27822137 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4454-67

PubMed: 26683357 ( click the link to review the publication )

Drug Discov Ther, 2016, 10(4):195-200

PubMed: 27594296 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71790-71801

PubMed: 27708243 ( click the link to review the publication )

Oncotarget, 2016, 7(2):1598-607

PubMed: 26624982 ( click the link to review the publication )

Oncotarget, 2016, 7(47):77622-77634

PubMed: 27769058 ( click the link to review the publication )
Oncotarget, 2016, 7(29):45214-45224

PubMed: 27286258 ( click the link to review the publication )

Oncotarget, 2016, 7(4):4559-69

PubMed: 26683226 ( click the link to review the publication )

Oncotarget, 2016, 7(11):12254-66

PubMed: 26930721 ( click the link to review the publication )

Oncotarget, 2016, 7(43):70845-70856

PubMed: 27683126 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45214-45224

PubMed: 27286258 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26824319 ( click the link to review the publication )

Oncotarget, 2016, 7(48):78883-78895

PubMed: 27713151 ( click the link to review the publication )

Oncotarget, 2016, 7(38):62572-62584

PubMed: 27613836 ( click the link to review the publication )

Mol Cells, 2016, 39(12):898-908

PubMed: 28008160 ( click the link to review the publication )

Sci Rep, 2016, 6:28528

PubMed: 27339427 ( click the link to review the publication )

FASEB J, 2016, 30(2):923-32

PubMed: 26546130 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(7):917-29

PubMed: 26075355 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-1462

PubMed: 25748087 ( click the link to review the publication )

Leukemia, 2015, 29(6):1390-401

PubMed: 25533804 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-14-2109

PubMed: 25712341 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4663-75

PubMed: 26116270 ( click the link to review the publication )

Biomaterials, 2015, 73:70-84

PubMed: 26402156 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Cell Rep, 2015, 12(4):622-35

PubMed: 26190113 ( click the link to review the publication )

J Control Release, 2015, 211:44-52

PubMed: 26031842 ( click the link to review the publication )

Elife, 2015, 4:e08153

PubMed: 26327694 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.455

PubMed: 25619841 ( click the link to review the publication )

Oncogene, 2015, 34(16):2138-2144

PubMed: 24909167 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.02.044

PubMed: 25737303 ( click the link to review the publication )
J Clin Endocrinol Metab, 2015, 100(5):E697-709

PubMed: 25675381 ( click the link to review the publication )

J Dent Res, 2015, 94(9):1243-50

PubMed: 26130255 ( click the link to review the publication )

Br J Haematol, 2015,

PubMed: 26310606 ( click the link to review the publication )

Structure, 2015, 23(2):407-17

PubMed: 25599643 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(2):639-50

PubMed: 25973303 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: ( click the link to review the publication )

J Immunol, 2015, 194(4):1695-701

PubMed: 25560410 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(2):223-30

PubMed: 25582703 ( click the link to review the publication )

Traffic, 2015, 10.1111/tra.12287

PubMed: 25824657 ( click the link to review the publication )

J Virol, 2015, 89(5):2643-58

PubMed: 25520503 ( click the link to review the publication )

J Virol, 2015, 89(5):2643-58

PubMed: ( click the link to review the publication )

Toxicol Sci, 2015, 10.1093/toxsci/kfv056

PubMed: 25766884 ( click the link to review the publication )

Sci Rep, 2015, 5:18251

PubMed: 26671574 ( click the link to review the publication )

Sci Rep, 2015, 5:13001

PubMed: 26306624 ( click the link to review the publication )

J Biol Chem, 2015, 290(50):29854-68

PubMed: 26483548 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(2):639-650

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 283(1):1-8

PubMed: 25576094 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.03.018

PubMed: 25817892 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):474-86

PubMed: 25422130 ( click the link to review the publication )

Phys Chem Chem Phys, 2015, 17(29):18971-9

PubMed: 26126833 ( click the link to review the publication )

Cell Signal, 2015, 27(10):1939-48

PubMed: 26163823 ( click the link to review the publication )

Int J Oncol, 2015, 46(2):474-86

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15:738

PubMed: 26483043 ( click the link to review the publication )

BMC Cancer, 2015, 15:444

PubMed: 26025442 ( click the link to review the publication )
Toxicol In Vitro, 2015, 29(8):1965-76

PubMed: 26165741 ( click the link to review the publication )

Biomed Rep, 2015, 3(6):797-801

PubMed: 26623018 ( click the link to review the publication )

Biosci Rep, 2015, 35(6)

PubMed: 26500282 ( click the link to review the publication )

Malar J, 2015, 14(1):200

PubMed: 25968882 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0143847

PubMed: 26630652 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134825

PubMed: 26284517 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:417586

PubMed: 26539491 ( click the link to review the publication )

Leuk Res, 2015, 10.1016/j.leukres.2015.08.007

PubMed: 26346348 ( click the link to review the publication )

Int J Hematol, 2015, 102(5):569-78

PubMed: 26341959 ( click the link to review the publication )

Anticancer Res, 2015,

PubMed: 26637878 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43540-56

PubMed: 26498353 ( click the link to review the publication )

J Bio Mater Res, 2015, 103(4):1476-84

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(38):40704-18

PubMed: 26513019 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(10):8200-9

PubMed: 25860931 ( click the link to review the publication )

Chem Biol, 2015, 10.1016/j.chembiol.2015.01.004

PubMed: 25728267 ( click the link to review the publication )

Oncotarget, 2015, 6(37):40141-57

PubMed: 26472029 ( click the link to review the publication )

Oncotarget, 2015, 6(35):38079-92

PubMed: 26472030 ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(10):8418-29

PubMed: 25762625 ( click the link to review the publication )

Oncotarget, 2015, 6(10):8200-9

PubMed: 25860931 ( click the link to review the publication )

Oncotarget, 2015, 6(22):18921-32

PubMed: 26254279 ( click the link to review the publication )

Oncotarget, 2015, 6(28):26347-58

PubMed: 26267322 ( click the link to review the publication )

Oncotarget, 2015, 6(1):56-70

PubMed: 25474141 ( click the link to review the publication )
Oncotarget, 2015, 6(17):14953-69

PubMed: 25879451 ( click the link to review the publication )

Sci Transl Med, 2014, 6(250):250ra112

PubMed: 25143362 ( click the link to review the publication )

Blood, 2014, 20;124(22):3250-9

PubMed: 25205118 ( click the link to review the publication )

Blood, 2014, 123(26):4120-31

PubMed: 24711662 ( click the link to review the publication )

J Clin Invest, 2014, 124(9):3757-66

PubMed: 25061876 ( click the link to review the publication )

Nat Commun, 2014, 5:3384

PubMed: 24594970 ( click the link to review the publication )

Nat Commun, 2014, 5:3772

PubMed: 24805825 ( click the link to review the publication )

Autophagy, 2014, 10(9):1603-21

PubMed: 25046115 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(6):1576-89

PubMed: 24634471 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(16):E1591-9

PubMed: 24715725 ( click the link to review the publication )

Cancer Res, 2014, 74(16):4458-69

PubMed: 24934808 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2803-15

PubMed: 24686171 ( click the link to review the publication )

Cancer Res, 2014, 74(11):3127-36

PubMed: 24755468 ( click the link to review the publication )

J Cell Biol, 2014, 205(6):771-80

PubMed: 24934156 ( click the link to review the publication )

Cell Death Differ, 2014, 21(12):1838-51

PubMed: 25034784 ( click the link to review the publication )

Mol Cancer, 2014, 13(1):159

PubMed: 24972933 ( click the link to review the publication )

Int J Cancer, 2014, 135(12):2950-61

PubMed: 24771510 ( click the link to review the publication )

Eur J Cancer, 2014, 51(1):1-8

PubMed: 25466507 ( click the link to review the publication )

Cancer Lett, 2014, 343(2):286-94

PubMed: 24120758 ( click the link to review the publication )

Br J Cancer, 2014, 110(9):2224-31

PubMed: 24691427 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1126

PubMed: 24625985 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1580

PubMed: 25522274 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):926-37

PubMed: 24482380 ( click the link to review the publication )
Mol Cancer Ther, 2014, 13(12):3013-23

PubMed: 25253782 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Biomed Nanotechnol, 2014, 10(4):717-23

PubMed: 24734524 ( click the link to review the publication )

J Am Heart Assoc, 2014, 3(1):e000520

PubMed: 24572252 ( click the link to review the publication )

J Nutr Biochem, 2014, 25(5):515-25

PubMed: 24613086 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt13):2898-909

PubMed: 24806960 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 21):4728-39

PubMed: 25179605 ( click the link to review the publication )

J Virol, 2014, 87(23):13035-41

PubMed: 24027330 ( click the link to review the publication )

Eur J Immunol, 2014, 44(6):1604-14

PubMed: 24643698 ( click the link to review the publication )

J Leukocyte Biol, 2014, 95(3):461-9

PubMed: 24231258 ( click the link to review the publication )

Sci Rep, 2014, 4:4164

PubMed: 24566666 ( click the link to review the publication )

Sci Rep, 2014, 4:6370

PubMed: 25231679 ( click the link to review the publication )

Cancer Gene Ther, 2014, 21(11):472-82

PubMed: 25323693 ( click the link to review the publication )

J Biol Chem, 2014, 289(17):11906-15

PubMed: 24570003 ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14075-88

PubMed: 24711452 ( click the link to review the publication )

J Biol Chem, 2014, 289(5):2687-700

PubMed: 24337575 ( click the link to review the publication )

J Proteome Res, 2014, 13(5):2223-38

PubMed: 24669782 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(19):3570-8

PubMed: 25022755 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2014, 307(9):C774-87

PubMed: 25143351 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(10):1350-7

PubMed: 25019382 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(6):742-57

PubMed: 24618845 ( click the link to review the publication )

World J Gastroenterol, 2014, 20(48):18207-15

PubMed: 25561788 ( click the link to review the publication )

J Biomed Mater Res A, 2014, 10.1002/jbm.a.35286

PubMed: 25046528 ( click the link to review the publication )

Hematol Oncol, 2014, 10.1002/hon.2179

PubMed: 25394177 ( click the link to review the publication )
Neurotoxicology, 2014, 42:33-48

PubMed: 24705302 ( click the link to review the publication )

J Vasc Interv Radiol, 2014, 25(12):1972-82

PubMed: 25439675 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 73(1):69-77

PubMed: 24190701 ( click the link to review the publication )

Cancer Chemoth Pharm, 2014, 10.1007/s00280-014-2451-7

PubMed: 24842158 ( click the link to review the publication )

PLoS One, 2014, 9(9):e103015

PubMed: 25181509 ( click the link to review the publication )

PLoS One, 2014, 9(6):e99211

PubMed: 24911872 ( click the link to review the publication )

PLoS One, 2014, 9(3):e89848

PubMed: 24595136 ( click the link to review the publication )

PLoS One, 2014, 9(9):e107009

PubMed: 25255316 ( click the link to review the publication )

Mol Cell Biochem, 2014, 398(1-2):165-73

PubMed: 25292312 ( click the link to review the publication )

J Nanopart Res, 2014, 42:33-48

PubMed: http://link.springer.com/article/10.1007/s11051-01 ( click the link to review the publication )

Biosciences biotechnology research asia, 2014, 10.13005bbra.1309

PubMed: ( click the link to review the publication )

Sci Rep, 2014, 4:5896

PubMed: 25077633 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Hepatology, 2013, 57(2):625-36

PubMed: 22991197 ( click the link to review the publication )

Nat Chem Biol, 2013, 10(1):61-8

PubMed: 24292069 ( click the link to review the publication )

Nat Protoc, 2013, 8(6):1155-68

PubMed: 23702832 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(11):3019-31

PubMed: 23584492 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5591-601

PubMed: 24004671 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(1):246-51

PubMed: 23248292 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(9):3501-6

PubMed: 23382202 ( click the link to review the publication )

Cancer Res, 2013, 74(1):56-67

PubMed: 24310398 ( click the link to review the publication )

Cell Rep, 2013, 4(4):751-63

PubMed: 23954782 ( click the link to review the publication )

Mucosal Immunol, 2013, 7(4):857-68

PubMed: 24280938 ( click the link to review the publication )

Int J Cancer, 2013, 133(6):1357-67

PubMed: 23463417 ( click the link to review the publication )
Breast Cancer Res, 2013, 15(6):R107

PubMed: 24207099 ( click the link to review the publication )

Br J Dermatol, 2013, 168(3):504-12

PubMed: 23445313 ( click the link to review the publication )

Free Rad Biol Med, 2013, 65:778-88

PubMed: 23973637 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e50

PubMed: 24158003 ( click the link to review the publication )

Pain, 2013, 154(11):2432-40

PubMed: 23891899 ( click the link to review the publication )

Expert Opin Drug Deliv, 2013, 10(10):1345-52

PubMed: 23937147 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(7):1299-309

PubMed: 23657945 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(5):747-58

PubMed: 23475956 ( click the link to review the publication )

Mol Oncol, 2013, 7(6):1012-8

PubMed: 23916134 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(3):578-87

PubMed: 23198928 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(2):383-90

PubMed: 23107612 ( click the link to review the publication )

FEBS J, 2013, 280(15):3609-20

PubMed: 23702335 ( click the link to review the publication )

J Virol, 2013, 87(21):11872-83

PubMed: 23986594 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(10):4456-69

PubMed: 23742826 ( click the link to review the publication )

Biochem Pharmacol, 2013, 85(11):1611-8

PubMed: 23523860 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )

J Trauma Acute Care Surg, 2013, 74(2):499-507

PubMed: 23354244 ( click the link to review the publication )

Mol Biol Cell, 2013, 35:215-22

PubMed: 24145151 ( click the link to review the publication )

Clin Exp Metastasis, 2013, 30(4):407-15

PubMed: 23412907 ( click the link to review the publication )

Retrovirology, 2013, 10(1):120

PubMed: 24156270 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1551-62

PubMed: 23877657 ( click the link to review the publication )

Toxicol Lett, 2013, 223(2):109-15

PubMed: 24055520 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 72(6):1335-42

PubMed: 24121478 ( click the link to review the publication )

Chembiochem, 2013, 14(12):1494-503

PubMed: 23881799 ( click the link to review the publication )
PLoS One, 2013, 8(9):e73710

PubMed: 24040035 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59390

PubMed: 23527180 ( click the link to review the publication )

PLoS One, 2013, 8(9):e75280

PubMed: 24086494 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82053

PubMed: 24312627 ( click the link to review the publication )

Eur J Haematol, 2013, 91(4):339-46

PubMed: 23869695 ( click the link to review the publication )

Leuk Res, 2013, 37(10):1302-8

PubMed: 23896061 ( click the link to review the publication )

J Int Med Res, 2013, 41(5):1505-19

PubMed: 23975859 ( click the link to review the publication )

Curr Protoc Chem Biol, 2013, 5(3):195-212

PubMed: 24391083 ( click the link to review the publication )

FEBS J, 2013, 280(15):3609-20

PubMed: 23702335 ( click the link to review the publication )

Blood, 2012, 119(24):5772-81

PubMed: 22538852 ( click the link to review the publication )

Blood, 2012, 119(11):2579-89

PubMed: 22262760 ( click the link to review the publication )

Nat Struct Mol Biol, 2012, 19(4):387-94

PubMed: 22407014 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(17):4669-81

PubMed: 22806876 ( click the link to review the publication )

Br J Pharmacol, 2012, 168(8):1868-77

PubMed: 23194305 ( click the link to review the publication )

Cancer Lett, 2012, 316(1):77-84

PubMed: 22082529 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(5):1487-96

PubMed: 22377766 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e295

PubMed: 22495350 ( click the link to review the publication )

FASEB J, 2012, 26(5):1855-65

PubMed: 22345405 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(11):2321-30

PubMed: 22964485 ( click the link to review the publication )

Mol Cancer Ther, 2012, 11(10):2243-53

PubMed: 22933706 ( click the link to review the publication )

Br J Haematol, 2012, 157(6):718-31

PubMed: 22533681 ( click the link to review the publication )

J Virol, 2012, 86(18):10112-22

PubMed: 22787216 ( click the link to review the publication )

J Virol, 2012, 86(24):13360-70

PubMed: 23015717 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2012, 303(3):E410-21

PubMed: 22669242 ( click the link to review the publication )
J Biol Chem, 2012, 287(13):10344-54

PubMed: 22318734 ( click the link to review the publication )

J Biol Chem, 2012, 288(2):1125-34

PubMed: 23209294 ( click the link to review the publication )

J Biol Chem, 2012, 288(4):2721-33

PubMed: 23209292 ( click the link to review the publication )

J Biol Chem, 2012, 287(41):34722-9

PubMed: 22910913 ( click the link to review the publication )

J Pharmacol Exp Ther, 2012, 343(1):184-97

PubMed: 22787116 ( click the link to review the publication )

Prostate, 2012, 72(10):1140-9

PubMed: 22127954 ( click the link to review the publication )

Cell Cycle, 2012, 11(9):1804-17

PubMed: 22510564 ( click the link to review the publication )

BMC Cancer, 2012, 12:541

PubMed: 23171055 ( click the link to review the publication )

Biol Reprod, 2012, 87(2):44

PubMed: 22592496 ( click the link to review the publication )

PLoS One, 2012, 7(1):e29541

PubMed: 22235305 ( click the link to review the publication )

PLoS One, 2012, 7(4):e34684

PubMed: 22514654 ( click the link to review the publication )

Exp Mol Pathol, 2012, 93(1):99-110

PubMed: 22475623 ( click the link to review the publication )

Steroids, 2012, 77(11):1025-32

PubMed: 22683670 ( click the link to review the publication )

J Biomol Screen, 2012, 17(9):1231-42

PubMed: 22927676 ( click the link to review the publication )

J Biomol Screen, 2012, 17(5):572-80

PubMed: 22357874 ( click the link to review the publication )

Biochem Cell Biol, 2012, 90(2):224-31

PubMed: 22397456 ( click the link to review the publication )

Saint Louis University, 2012, 2012/0270829

PubMed: ( click the link to review the publication )

Sarcoma, 2012, 2012:805614

PubMed: 22919280 ( click the link to review the publication )

Blood, 2011, 118(14):3922-31

PubMed: 21841164 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Development, 2011, 138(14):2903-8

PubMed: 21653611 ( click the link to review the publication )

Br J Haematol, 2011, 155(5):588-98

PubMed: 21950728 ( click the link to review the publication )

J Virol, 2011, 85(6):2781-92

PubMed: 21228236 ( click the link to review the publication )

J Biol Chem, 2011, 286(18):16018-29

PubMed: 21454483 ( click the link to review the publication )
Exp Cell Res, 2011, 317(18):2671-82

PubMed: 21871886 ( click the link to review the publication )

Int Immunopharmacol, 2011, 11(12):2242-5

PubMed: 21979495 ( click the link to review the publication )

PLoS ONE, 2011,

PubMed: 21949687 ( click the link to review the publication )

PLoS One, 2011, 6(8):e23712

PubMed: 21887304 ( click the link to review the publication )

Cell Biochem Biophys, 2011, 60(3):173-85

PubMed: 21132543 ( click the link to review the publication )

University of Porto, 2011, Mireia Vila Gasull

PubMed: ( click the link to review the publication )

Glia, 2010, 58(16):1961-76

PubMed: 20830808 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

J Virol, 2010, 84(18):9439-51

PubMed: 20592098 ( click the link to review the publication )

J Biol Chem, 2010, 285(52):41074-86

PubMed: 20956535 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description

Targets

NF-κB ^[6] ()	20S proteasome ^[1] (Cell-free assay)
	0.6 nM(Ki)

In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. ^[2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
NCI-H1838	NGHD[3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTRzOE[uN\|Ih\|ryP	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
IMR-5	NIrERVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDlRYpKSzVyPUO0NFkvPjJizszN	NH[0fHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
TE-441-T	NV3uUVhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnG3TWM2OD1{NUKxMlch\|ryP	MmjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
U-698-M	M1vDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPrfYRKSzVyPUKyOlIvOTVizszN	MmTtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
COLO-824	MlrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlT0TWM2OD1zMk[xMlc5KM7:TR?=	MmHuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
P31-FUJ	M4Ta[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{n6c2lEPTB;MUGxNk44PSEQvF2=	MkfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
KY821	M{PGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TjdGlEPTB;MUCzOk4xPCEQvF2=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
RPMI-8866	NHLtbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{excGlEPTB;MUCwOk4zQCEQvF2=	NWXqSZM5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
TC-YIK	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTd6MT6wNUBvVQ>?	NXXubFc1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
MS-1	Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFzl[oRKSzVyPUe1PU41OiCwTR?=	NFHPenI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
DMS-153	MoHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYGxWYsxUUN3ME23OFYvQDNibl2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SUP-T1	M1vRUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTZ6Nj6wOEBvVQ>?	NHLnb5o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SCC-15	NXOzNopxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;mXWlEPTB;Nk[3MlQ4KG6P	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MSTO-211H	NU\PfWxpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3r1U2lEPTB;NUe0MlI3KG6P	Mm[3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
J-RT3-T3-5	NHfpOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\ZTWM2OD13M{KuOVchdk1?	NF;KeFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H889	MnKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTFTWM2OD12NkGuPVIhdk1?	MkWyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
CPC-N	MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnRZYhyUUN3ME20NFMvPzdibl2=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
COLO-668	NWP3SlFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjS[5NKSzVyPUSwN{42PyCwTR?=	NYXEfIYyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H226	NGHzfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTRyMz6yN{BvVQ>?	NWCxWoo6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
TUR	NFrB[opIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV\GPWdQUUN3ME2zPVYvPjFibl2=	Mmq1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
DEL	NWC4fJNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXxXo1KSzVyPUO5NU4zPyCwTR?=	NGj6[mU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H1963	NILJXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTN6Nj6xPUBvVQ>?	Ml61QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
CA46	NXG5OplQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlP5TWM2OD1\|N{OuOlMhdk1?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SNU-C1	M3[4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTN4Mj6wPUBvVQ>?	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
THP-1	Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jBeGlEPTB;M{KyMlYhdk1?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SCH	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37ZNmlEPTB;M{KyMlIzKG6P	MoqyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H1522	NYLCXm82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTNyNz6wOUBvVQ>?	NYHHd2hCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
LNCaP-Clone-FGC	M{LXXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIe4XGdKSzVyPUK5OU4zPiCwTR?=	MkHqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H2171	NVHnfXNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTJ6OD65NkBvVQ>?	NEnkNJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H187	NGDwXnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIn6UoRKSzVyPUK4O{4xQCCwTR?=	Mlv0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
KASUMI-1	NILBe5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mon0TWM2OD1{OEOuNFUhdk1?	M4LGc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SK-MEL-2	NF;Jc2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1j0WWlEPTB;MkixMlkhdk1?	NIP2Vos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
EW-22	NEfhUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFK4S\|lKSzVyPUK2N{44PSCwTR?=	MnT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H1299	M33VbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTJ4MT63NUBvVQ>?	MofMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
COR-L279	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1q1RmlEPTB;MkWyMlE4KG6P	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H1155	NV3ibWRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTiTXZKSzVyPUKzNE4{OiCwTR?=	NIDkdnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H1395	M4P2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MluyTWM2OD1{MUCuNVMhdk1?	M4Tj[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
KM-H2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\odWlEPTB;MUm3MlA2KG6P	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H209	NVvT[2FwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2r1[2lEPTB;MUm2MlUzKG6P	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H510A	NEDIeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3q5emlEPTB;MUi1MlM4KG6P	M4PqfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H1304	NITweZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVvRfYpNUUN3ME2xOlkvOjFibl2=	NF3QNYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SCLC-21H	NIXHWmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fucmlEPTB;MUW5MlQyKG6P	NEjkeHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H524	MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTF3OT6xJI5O	M2rNZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MC116	M2C4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjqSGxKSzVyPUG0PE45PSCwTR?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
BV-173	M3j4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTF{Mj63NUBvVQ>?	NVP6[ldbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
MHH-CALL-2	M4Xoe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\HPHNTUUN3ME2xNVUvPyCwTR?=	MkXxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H1650	NFe1blJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTFzNT6yPUBvVQ>?	M4rySFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
ST486	Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTFzND6wOkBvVQ>?	MoL2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
GR-ST	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LGfGlEPTB;MUGzMlM1KG6P	NH\XWXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SIG-M5	M{\JW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXriVFh{UUN3ME2xNFUvODZibl2=	MlHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H1770	M4DXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTFyMj60PUBvVQ>?	M3jsTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
RH-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvWTWM2OD17OT64OUBvVQ>?	NXrmUVJjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
AM-38	M2X6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvaOmhVUUN3ME24PE4xQCCwTR?=	NH[xZ3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
RL	NV7v[Xo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2ftR2lEPTB;OE[uNFkhdk1?	NFLVe5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
CAL-148	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGr3XGxKSzVyPUixMlg1KG6P	MlHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SK-N-FI	NGTjW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoD6TWM2OD16MD6yJI5O	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
EW-11	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXmcY5KSzVyPUe4MlUzKG6P	NWfkN4d1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
EW-13	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLPTWM2OD15Nz63OkBvVQ>?	MlPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
ALL-PO	NXTxS245T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{njZWlEPTB;N{euOlYhdk1?	Mo\NQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
KP-N-YS	NVLEWYlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XlTmlEPTB;N{[uO\|Qhdk1?	NGnxbGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
KMS-12-PE	MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nsN2lEPTB;N{[uNlQhdk1?	NVLKSY5MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H128	MkSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjDTWM2OD15ND63O{BvVQ>?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H322M	NWDkTG5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlq0TWM2OD14Nj6xNUBvVQ>?	Ml;wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
BT-474	NUj4VFFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\TN2lEPTB;NkWgcm0>	M1r0O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MRK-nu-1	NIPNOGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\keIpKSzVyPU[xMlgzKG6P	Mn7lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
YT	NX\rc5FCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTZzLkigcm0>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LP-1	M17veWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\4UGpXUUN3ME22NU4zQCCwTR?=	NVPlRZdKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
P30-OHK	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYK4boRtUUN3ME21OE43OSCwTR?=	NEXabYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-N87	NXrMU2l6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTV2LkG4JI5O	NUKwT2RCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
TALL-1	NGqzZYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;HOmJWUUN3ME21N{46OSCwTR?=	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MC-CAR	NHWzV\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXqN3ZKSzVyPUWxMlUzKG6P	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H720	NYLKT3k5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PS[mlEPTB;NUGuNVEhdk1?	NVfhPGN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
RS4-11	M1vDfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTVyLki4JI5O	NIHQUIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
DMS-79	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPrTWM2OD13MD63NUBvVQ>?	NHXXcXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H716	NYDTRXBnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTR6LkixJI5O	M4DKPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
RPMI-6666	NELFdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnaUWU5UUN3ME20OU45QSCwTR?=	MojmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
L-428	NUnjb2l4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvWTZVzUUN3ME20N{45PiCwTR?=	NXTnWYVCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SKM-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nX[WlEPTB;NEKuOlMhdk1?	NGDoO3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H2227	NUfkSJZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEG3bFZKSzVyPUSwMlQ6KG6P	NGi1e3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SHP-77	M2O0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXmTWM2OD1\|OD6wN{BvVQ>?	NFmxdGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
D-283MED	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEPIdm1KSzVyPUO3Mlc6KG6P	MlzMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
MDA-MB-134-VI	NHfm[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTN3Lki3JI5O	NITaW4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
C8166	MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1Sy[WlEPTB;M{WuO{BvVQ>?	NVvZeJVwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
UACC-812	M2TBV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHjzbmFKSzVyPUO1MlQ1KG6P	MoDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
ES3	M4PzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTN3LkG5JI5O	NIfqcIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SK-MEL-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjUVHpKSzVyPUO1MlE4KG6P	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
KARPAS-422	M2\y[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3TXm1zUUN3ME2zOU4xPCCwTR?=	NFXH[4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H719	MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml3PTWM2OD1\|ND6zNUBvVQ>?	NH7iNFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H526	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHmzN\|FKSzVyPUOyMlU1KG6P	MmPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
EW-3	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzhRpE3UUN3ME2zNE42QSCwTR?=	MmjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
OCI-AML2	NXzGTplTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1rodWlEPTB;MkmuOlkhdk1?	NGnpUI09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
ECC4	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLVTWM2OD1{OD63PUBvVQ>?	NGHGNnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
WSU-NHL	NUDTeoZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVKyc3BVUUN3ME2yPE4{QSCwTR?=	M2fWR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NH-12	MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;OV2lEPTB;MkeuOlchdk1?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LU-165	NHfKWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\VRmlEPTB;Mk[uO\|Ihdk1?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
REH	NXLDV4d4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jXNmlEPTB;Mk[uOFEhdk1?	NFnaOlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LS-1034	M1XXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnS2TWM2OD1{NT63OUBvVQ>?	NX7mTZUyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
HDLM-2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2jGNmlEPTB;MkSuOVQhdk1?	NHrtZoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
EC-GI-10	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXzTWM2OD1{ND6yN{BvVQ>?	MoLhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
IM-9	NEfnW\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;LS5dtUUN3ME2yN{42PCCwTR?=	MkfmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
DOHH-2	M4r0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rxWGlEPTB;MkOuOFUhdk1?	NWnuWWU4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SIMA	M{n2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTJ\|LkO4JI5O	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
EW-12	NF;WWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnTcFhmUUN3ME2yN{4yPyCwTR?=	M{HWWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
HCC2157	NFHkR\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2S1TmlEPTB;MkOuNVMhdk1?	NWfVbGw{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H82	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnGTWM2OD1{Mz6wNkBvVQ>?	NGHHNpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
IST-MES1	NH[5SZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmO4TWM2OD1{Mj63O{BvVQ>?	M{DsRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H446	NWDoOIgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mln3TWM2OD1{MT6xPEBvVQ>?	NX;HfZBiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SF539	NGPMVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUjMPGZ3UUN3ME2yNE43PyCwTR?=	NIHSdJI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
TE-6	NVfwOXJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlXuTWM2OD1{MD6wPEBvVQ>?	M1LYTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
HCC2218	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\S[GlEPTB;MUmuOUBvVQ>?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
DG-75	NEPsfYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TBTGlEPTB;MUiuOlEhdk1?	M{LETVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCCIT	MmrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTF6LkO2JI5O	M{PFV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
EoL-1-	MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvJTWM2OD1zOD6zNUBvVQ>?	MkH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
EB2	MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTF6LkC4JI5O	NEDFd\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NB14	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDiTnI3UUN3ME2xO{46QCCwTR?=	M2P0cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
EW-18	MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTaTWM2OD1zNz65OkBvVQ>?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MFM-223	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nxPWlEPTB;MUeuPVEhdk1?	NV7oVWlORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
COLO-800	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHm3ZXZKSzVyPUG3MlY1KG6P	NGe3UnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
GOTO	M1zGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljJTWM2OD1zNz6wOkBvVQ>?	NYPsfJl6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H1436	NITpV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfCN3RKSzVyPUG3MlAyKG6P	NIG2NXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
U-87-MG	NVnPWIdVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTF4Lke2JI5O	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
TGW	M3Psc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPGco83UUN3ME2xOk41QCCwTR?=	M3fDT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
JAR	NHvPc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWDTb45OUUN3ME2xOk4yOyCwTR?=	MlP3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NB7	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTF3LkmyJI5O	M2W1XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-SNU-1	NUj6WpBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLSfmVUUUN3ME2xN{4yQSCwTR?=	Mn;YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
JVM-3	NGDHR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPlcXVKSzVyPUGyMlk6KG6P	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H1581	NYO3O\|J7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2LYUGlEPTB;MUKuNlghdk1?	NITKZWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H23	MlfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XTdGlEPTB;MUKuNVIhdk1?	M1nxeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
HCC1599	NYDncpBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTFzLkmxJI5O	NXLtXow5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
ES5	M2LVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvJWnlKSzVyPUGwMlM5KG6P	NUf2N\|BDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H2081	MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIH0V5hKSzVyPUGwMlA6KG6P	NWDRd5hRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
CTB-1	NWe2NotTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTlwNkegcm0>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
DMS-114	NHfjZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjOTWM2OD17Lk[yJI5O	NV7QTIxMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SK-NEP-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTlwMEGgcm0>	NYPFPIk4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
ATN-1	NFj2e41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRThwOEmgcm0>	NYjWR4QxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
MLMA	NGDw[2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTDTWM2OD16Lki1JI5O	M1LmR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NB6	M4DvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFT2clZKSzVyPUiuOFghdk1?	MlLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
MN-60	NH\N[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfaTWM2OD16LkG0JI5O	NHL1UZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
KG-1	MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3XZplKSzVyPUeuPVQhdk1?	NETWNpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
L-363	M4[zTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTdwNzDuUS=>	MkmzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-SNU-16	M4jkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrVRWRKSzVyPUeuOlUhdk1?	M1\yfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H1694	NGP4SFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLtTWM2OD15LkW4JI5O	MnfyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LU-134-A	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rzTmlEPTB;Nz6zPUBvVQ>?	MnHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
JVM-2	Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTdwMkigcm0>	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SU-DHL-1	NHLPT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfTW3l{UUN3ME23MlI1KG6P	NWjw[FNJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H345	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE[3e5pKSzVyPUeuNkBvVQ>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NB1	M{LoSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjIRmtKSzVyPU[uPFghdk1?	MlrMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H2196	NFzQTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXJ[4NKSzVyPU[uPEBvVQ>?	M17WUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
GDM-1	NEjZbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTZwN{egcm0>	NVTMW294RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
BC-3	M4nsVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;YfmlEPTB;Nj62NUBvVQ>?	NVHGb5oxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
D-502MG	NU\VcnhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzLeoJKSzVyPU[uN\|chdk1?	M1;uWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
LU-65	MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLaRpFKSzVyPUWuPFQhdk1?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NCI-H1417	M2m0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTVwNUGgcm0>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
EW-1	NVHtdnRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPaXoVKSzVyPUWuN\|Ehdk1?	NXPLXWptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SW962	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTVwMkGgcm0>	NXLZbHY2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-SNU-5	NIXhN2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTyTWM2OD13LkG3JI5O	MoTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LU-139	NF:wcWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYL0VYdlUUN3ME21MlE{KG6P	M{jvcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
CHP-126	NYDtTWxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEO5eXdKSzVyPUWuNFYhdk1?	Ml7KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
SBC-1	NVfUVWE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PKSGlEPTB;NT6wNUBvVQ>?	NU\ZcWtoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
JiyoyeP-2003	MnvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYX6[\|FnUUN3ME21JI5O	M3TBblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MHH-NB-11	Mn71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXrTWM2OD12LkmxJI5O	MmLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
MHH-PREB-1	NVPTV5RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4j6WmlEPTB;ND64OkBvVQ>?	M1;jbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
IST-SL1	NHfZXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;LWId{UUN3ME20MlY5KG6P	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
HL-60	Mn7JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7mcGVwUUN3ME20MlY4KG6P	M3TPO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NALM-6	M3nScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPOS4U1UUN3ME20MlQ6KG6P	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
Raji	NE\MOGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlnxTWM2OD12LkS2JI5O	M1X3cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NOMO-1	Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTRwM{Ogcm0>	NF\pXZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
TE-12	M4nLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFexSm5KSzVyPUSuNlUhdk1?	MmGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LB647-SCLC	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2X4NGlEPTB;ND6yNkBvVQ>?	MlToQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
OMC-1	NIDvfI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDhT\|ZNUUN3ME20MlE5KG6P	NEKxXng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H1648	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPoOIpKSzVyPUSuNVMhdk1?	NFK0dWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
K-562	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF64OZJKSzVyPUSuNVIhdk1?	MnrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H2141	NV[wOGpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;Y[m1KSzVyPUSuNFUhdk1?	NULmWmMzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
HD-MY-Z	NVPySHBXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\kdHRKSzVyPUOuPVMhdk1?	Ml[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
RCC10RGB	NX3Uflh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRTNwOUOgcm0>	NXPoZVkyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
COLO-320-HSR	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTNwOUKgcm0>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
RL95-2	NWXabYI3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVPrWZBNUUN3ME2zMlc6KG6P	M4SzbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
LC-1F	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTNwN{Sgcm0>	M4njW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NMC-G1	M171UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTNwNkigcm0>	MlzBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
COLO-684	M3mzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jtXmlEPTB;Mz62OkBvVQ>?	M1zTelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
DJM-1	NUm4bYxMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\ZZoVEUUN3ME2zMlY{KG6P	NU\KbVBZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
EVSA-T	MofaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTNwNjDuUS=>	NVfOOFBQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
no-11	M1LsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfiR\|d5UUN3ME2zMlU2KG6P	MnXLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
MZ1-PC	NHzobZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWSzVIhrUUN3ME2zMlU1KG6P	M4LIV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
HCC1187	NIXENm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlP5TWM2OD1\|LkW0JI5O	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
KARPAS-45	NEex[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPW[HIzUUN3ME2zMlU1KG6P	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
RPMI-8402	NGTpSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRTNwNTDuUS=>	MnHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LOXIMVI	NHK3cXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XwfWlEPTB;Mz61JI5O	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MEG-01	NHjJVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1r6ZmlEPTB;Mz60PUBvVQ>?	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LAMA-84	NXTBSlBTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkeyTWM2OD1\|LkS5JI5O	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
COR-L88	NHmwZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\ofodKSzVyPUOuOFchdk1?	NW\O[nhtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
TE-15	NHfH[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTNwNEOgcm0>	NIjGU5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
DB	M3rPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DlVWlEPTB;Mz60NUBvVQ>?	NXe5XWdwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
LB996-RCC	NWHpPWJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTNwNDDuUS=>	MmHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NEC8	MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTNwM{Wgcm0>	M4Hu[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SK-N-DZ	NWS1bplHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVyxbXA6UUN3ME2zMlI3KG6P	NYfTc\|NERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
CW-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTNwMkGgcm0>	NYfxU2V3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SK-PN-DW	M330NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HDd2lEPTB;Mz6xOEBvVQ>?	NFvyZo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
CGTH-W-1	Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTNwMTDuUS=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
MONO-MAC-6	NV33coFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3VVFBKSzVyPUOuNUBvVQ>?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
KARPAS-299	NWnDVINsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rSemlEPTB;Mz6wOkBvVQ>?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
HT	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTNwMEKgcm0>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SW954	NFHBcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\US2lEPTB;Mj65JI5O	M1X1clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MOLT-16	NFi5R5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjXTWM2OD1{Lki5JI5O	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
C2BBe1	NXPNWWVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDve4pKSzVyPUKuPFkhdk1?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
ETK-1	NH\U[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTJwOESgcm0>	M37sVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
CTV-1	NXvwSFJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTJwODDuUS=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
EW-16	M4Hjb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTyeWJKSzVyPUKuO\|Uhdk1?	NEm4[I49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
Mo-T	MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3Tk[2lEPTB;Mj63OEBvVQ>?	NVLtRnhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
EB-3	M3OweGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVu5dItUUUN3ME2yMlY3KG6P	MljBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LB1047-RCC	NYH0XG5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUT5ZmhuUUN3ME2yMlU4KG6P	MnTkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
KNS-81-FD	NUPZVpczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVKwXVRsUUN3ME2yMlQ5KG6P	NF\IOY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NB69	NWC1dGdFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTJwNE[gcm0>	NWSxXW9HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H64	MnrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXfJR\|UxRTJwNESgcm0>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
KU812	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYLJR\|UxRTJwNEKgcm0>	NHjBTpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H748	NF7S[G1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jEdWlEPTB;Mj6zPUBvVQ>?	NEfWUZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
ARH-77	M2\yNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;pXIh6UUN3ME2yMlM5KG6P	NGfXOXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SCC-3	MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37heGlEPTB;Mj6zO{BvVQ>?	MkLHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
RPMI-8226	NW\6SGZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrS[HhKSzVyPUKuN\|Uhdk1?	NIrKbmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NB10	MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnP3TWM2OD1{LkOyJI5O	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
BC-1	NFv4U2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTJwM{Ggcm0>	NHLwZ2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NB5	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjncWI6UUN3ME2yMlI4KG6P	NUHTSnNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
KMOE-2	NXTzWHJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPnTWM2OD1{LkKzJI5O	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SJSA-1	NUTzeJRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVr6[5ZuUUN3ME2yMlIyKG6P	NYjXdpp{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
ES4	M{n3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm[1TWM2OD1{LkG2JI5O	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
KGN	M37aTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4Lkd2lEPTB;Mj6xOUBvVQ>?	M4X3flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
EKVX	NX7iS3RDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NG\JdpNKSzVyPUKuNVQhdk1?	MlH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
MOLT-4	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HSSGlEPTB;Mj6xN{BvVQ>?	NFXFVIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
KE-37	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnyxTWM2OD1{LkGzJI5O	NXj5dJUxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
HH	NILWNYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLKTWM2OD1{LkGzJI5O	NGfOT2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
GT3TKB	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTJwMUKgcm0>	Mo\FQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
BL-70	NWm2SINST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYX5PFdnUUN3ME2yMlEzKG6P	NWjmU4dsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NOS-1	NFW0VFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYr1cYxtUUN3ME2yMlEyKG6P	Mlm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
EW-24	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDXZXR3UUN3ME2yMlA5KG6P	NWe3WYN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
LAN-6	NXf5PFFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn75TWM2OD1{LkC1JI5O	NXnx[HNiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NB17	M3y1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfCTWM2OD1{LkC0JI5O	Ml\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LS-123	M2rXeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPoPGFKSzVyPUKuNFIhdk1?	NHzjcGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NB13	NIGwXI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHOwXoNKSzVyPUKgcm0>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
NKM-1	MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTJibl2=	NW\IS25FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
697	NHe1OVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXnRWY2UUN3ME2xMlk6KG6P	NFrRS\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
BE-13	NGnORlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLRXppKSzVyPUGuPVMhdk1?	NHHYWo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
MPP-89	NIrVbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTFwOEmgcm0>	MnGzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
Becker	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDjVVdwUUN3ME2xMlg{KG6P	NGr3Z3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
MV-4-11	NHXLXJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYO2V3JGUUN3ME2xMlgzKG6P	M3jYSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
GB-1	M4XIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;lTWM2OD1zLkixJI5O	NED6SJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H1092	NYTUeJBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYXZeIdVUUN3ME2xMlghdk1?	M2TpNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H2126	M1vBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPPWJpKSzVyPUGuPEBvVQ>?	NVqz[2lmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
LC4-1	NYrFXm4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXHidVAxUUN3ME2xMlc6KG6P	NVXVNmpWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
U-266	NEXTNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITq[VBKSzVyPUGuO\|Yhdk1?	NI\zXnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
KURAMOCHI	NVLKZm1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVrr[GRlUUN3ME2xMlczKG6P	M2LKdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
TGBC1TKB	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHjTWM2OD1zLkexJI5O	M2PMflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
EHEB	M4rT[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fBeGlEPTB;MT62O{BvVQ>?	NVXiV5gzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
GCIY	MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfp[GM3UUN3ME2xMlYzKG6P	NXjwOZJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
HEL	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVL3VVVsUUN3ME2xMlYyKG6P	NHnUeZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NB12	M{W3VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRTFwNU[gcm0>	MorpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NCI-H69	M3PKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkO4TWM2OD1zLkW0JI5O	NXXCfFduRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
LS-411N	NEjHcJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrnVYFCUUN3ME2xMlU{KG6P	NHvsXWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
PF-382	MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rCcWlEPTB;MT60O{BvVQ>?	NGLxNWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
CAS-1	NGfiVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4XmfWlEPTB;MT6zO{BvVQ>?	M1zhdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
L-540	M3LaOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrVZXdKSzVyPUGuN\|chdk1?	NFnRcZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
ECC12	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk\uTWM2OD1zLkO3JI5O	NVzubnI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
DU-4475	NYO2[VZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;EWWlEPTB;MT6zOkBvVQ>?	NXS3Spo2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
OPM-2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYK0[pVKUUN3ME2xMlM{KG6P	MkW3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
IST-SL2	NXjMb5k{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIS1PFJKSzVyPUGuN\|Ehdk1?	NHPXfoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
Calu-6	NEPLV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XWeWlEPTB;MT6yPUBvVQ>?	M1nUWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
CMK	MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfKTWM2OD1zLkK5JI5O	M4Gy[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
A3-KAW	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzNSmpMUUN3ME2xMlI5KG6P	NUnkUY9HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
K5	M3fKSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTFwMkigcm0>	MkD0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
KM12	NESyWllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTFwMkegcm0>	NFHuZVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SR	MofzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17QZ2lEPTB;MT6yOUBvVQ>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
BL-41	NEPjWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmqzTWM2OD1zLkK1JI5O	Mme3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
Daudi	M1nYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3P6fmlEPTB;MT6yNkBvVQ>?	NX\iTIdPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
NCI-H1882	NFnicYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTFwMjDuUS=>	NUPzXGZPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
TE-8	MlnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jKfmlEPTB;MT6xPUBvVQ>?	NYfEXYp{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
HAL-01	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HUUGlEPTB;MT6xPEBvVQ>?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
EM-2	NFnYTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTFwMU[gcm0>	NHHEUpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
CCRF-CEM	MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnROWNKSzVyPUGuNVMhdk1?	MoXwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
D-392MG	NUfrbIszT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFnxZmZKSzVyPUGuNUBvVQ>?	NIj5fHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
MZ7-mel	NUHpTnJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXN[XlKSzVyPUGuNFkhdk1?	M4\TR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
VA-ES-BJ	NUHSXVRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTFwMEmgcm0>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SK-MM-2	M3vFVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NID1VXVKSzVyPUGuNFkhdk1?	NEnlWmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LC-2-ad	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfOXpA1UUN3ME2xMlA5KG6P	NUfGdWszRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
RKO	NH:1XXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvKTWM2OD1zLkC2JI5O	NW\pb41GRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
TE-10	NUj0eZozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULaTVRmUUN3ME2xMlA{KG6P	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
TE-1	NWnWO2dVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjDPJZCUUN3ME2xMlA{KG6P	MmLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
PSN1	NEHodGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTFwMEGgcm0>	NGTTR3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
SW872	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEH3Nm9KSzVyPUCuPVk3KG6P	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
HC-1	NEXIb5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUPJR\|UxRTBwOUe1JI5O	NIHrVHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
KALS-1	M1\hbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTBwOUK1JI5O	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SF268	M4DhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTBwOUKzJI5O	Ml;tQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
IST-MEL1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3p[lFKSzVyPUCuPVE4KG6P	MmroQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
RXF393	NVLibYRnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;DTWM2OD1yLkmxOEBvVQ>?	M4C4TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
SNB75	MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3IW2NuUUN3ME2wMlkyOiCwTR?=	NI[xWFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
NCI-H1355	NVfQPXZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoD3TWM2OD1yLki5OUBvVQ>?	M3TxR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
TE-5	NXTSNGR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfP[3VsUUN3ME2wMlg3PSCwTR?=	MlrIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
QIMR-WIL	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfMW\|JKSzVyPUCuPFg6KG6P	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SK-LMS-1	MnrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTBwOEW0JI5O	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SW684	M2\tV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn[xTWM2OD1yLkiyNUBvVQ>?	NIfpR4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
ML-2	NF;yZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVjieJc3UUN3ME2wMlgzOSCwTR?=	NFzuNYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
D-263MG	NGf1V5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWmwZoJTUUN3ME2wMlgxPyCwTR?=	NH3WWWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LB2241-RCC	MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7RTWM2OD1yLkiwOEBvVQ>?	NEHsW5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
GI-1	NH:xWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXiTWM2OD1yLke2OEBvVQ>?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
ES7	NW\IdHVST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfjTWM2OD1yLke2OkBvVQ>?	M1zxfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
LS-513	NE\UbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnPtTWM2OD1yLkezPUBvVQ>?	M2DNXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
KINGS-1	M{LvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LVbGlEPTB;MD63NlIhdk1?	NGnZNnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
UACC-257	NXnk[od3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXOZnVvUUN3ME2wMlcyKG6P	MnjmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
LB373-MEL-D	NWLoSZRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\RTWM2OD1yLkegcm0>	NWjs[opuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SF126	NVTUN\|E6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jXdmlEPTB;MD63NFEhdk1?	NGThbXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
Ramos-2G6-4C10	NIDHcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTBRVd4UUN3ME2wMlY6OyCwTR?=	NEi4cWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
TK10	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDsTWM2OD1yLk[3PUBvVQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
D-336MG	MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUXMTHFMUUN3ME2wMlY2PyCwTR?=	Mmj0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
BB49-HNC	NI\jO\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXL1cFg3UUN3ME2wMlY2OiCwTR?=	NVXkS3c3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
HOP-62	NVzwWm1CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTBwNkS3JI5O	NGnMfmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
LB831-BLC	NWj6[4FDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrHTWM2OD1yLk[0NUBvVQ>?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
GI-ME-N	NYDPN\|VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nOVmlEPTB;MD62N\|Qhdk1?	NGDSeGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
A4-Fuk	MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmn5TWM2OD1yLk[yN{BvVQ>?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
HT-144	M2H2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoC2TWM2OD1yLkW3OkBvVQ>?	M3PtVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
COLO-829	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTBwNkG0JI5O	M33lXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
NCI-H747	NV;mOI16T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTBwNUO5JI5O	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
CESS	NWfGbZI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTBwNUO4JI5O	NFf2TY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
HUTU-80	MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\KbmRKSzVyPUCuOVM{KG6P	NVnXSng2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
DSH1	NYjOfIZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTBwNEigcm0>	NVqxe4x5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
LB771-HNC	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3G2bGlEPTB;MD60O\|Qhdk1?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
CP66-MEL	MkjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DU[2lEPTB;MD60O\|Mhdk1?	MkHjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
OCUB-M	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;peGlEPTB;MD60OFchdk1?	Mn;QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
MFH-ino	NXLKOVhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHCfG1TUUN3ME2wMlQ1OyCwTR?=	M{flU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
OS-RC-2	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjzVHo3UUN3ME2wMlQ1KG6P	MmLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
HCE-T	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTBwNEO5JI5O	Mo\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
ES1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkm1TWM2OD1yLkSzJI5O	M3nITVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
LB2518-MEL	M2m0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDPW4M2UUN3ME2wMlQzPSCwTR?=	NVjjZnA6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
ACN	MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlLZTWM2OD1yLkSxO{BvVQ>?	M{HOZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
D-247MG	M4rDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXG0blR1UUN3ME2wMlQyOyCwTR?=	NHvifVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
HCC2998	NFnhepRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnvQTWM2OD1yLkSxNkBvVQ>?	NFHRbm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
MZ2-MEL	NWjTXIlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTBwNEC3JI5O	M3Xic\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
ES8	MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVH3OVVDUUN3ME2wMlQhdk1?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
A388	Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTBwM{W2JI5O	NETHO4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
KS-1	NGPRcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTBwM{Sgcm0>	NFXnN\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
BB30-HNC	M2\CXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnjUW9KSzVyPUCuN\|M2KG6P	M4\BOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
ONS-76	NUjLSJpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoTFTWM2OD1yLkOzJI5O	NYDLN5J2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
D-542MG	M4D0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXK[HFKSzVyPUCuN\|I6KG6P	NXXufIFuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
BB65-RCC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHy5WVVKSzVyPUCuN\|A1KG6P	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
LOUCY	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkP1TWM2OD1yLkK5N{BvVQ>?	MlnzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
OVCAR-4	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDaS4tKSzVyPUCuNlg6KG6P	M{exR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
LXF-289	MlTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLkbVhKSzVyPUCuNlY6KG6P	NFXQVJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw{OjVyNEGvK\|5USU6JRWK8M4E,
KNS-42	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjwU4JKSzVyPUCuNlU5KG6P	NXewT3ptRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
8-MG-BA	M{TIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUTJR\|UxRTBwMkWgcm0>	MkL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
NTERA-S-cl-D1	NGH5RnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrTWXZKSzVyPUCuNlQ{KG6P	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
A101D	M3jyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfZfpNOUUN3ME2wMlIzPSCwTR?=	M1PGfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
MMAC-SF	NYjKT\|FKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTsWJNlUUN3ME2wMlIyPiCwTR?=	MlrEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
no-10	M2nkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTnTWM2OD1yLkKxJI5O	MkW5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
A253	MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWj0UlNvUUN3ME2wMlIxQCCwTR?=	M2PzbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFMzPTB2MT:nQnNCVkeHUkyvZV4>
TE-9	M1PvS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnH6TWM2OD1yLkG4NkBvVQ>?	NVLTO4xLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
SH-4	MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPRWmpmUUN3ME2wMlE4OyCwTR?=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNlUxPDFxJ{7TRW5ITVJ:L3G+
SK-UT-1	NE[0WHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jOUGlEPTB;MD6xOlMhdk1?	MlPqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN\|I2ODRzLze+V2FPT0WUPD;hQi=>
ES6	M1\3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnHRTWM2OD1yLkCwNlEhdk1?	NXH1U496RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOzJ3MESxM{c,W0GQR1XSQE9iRg>?
human PBMC	M4DDR2Z2dmO2aX;uJGF{e2G7	M37sfFExOCCwTR?=	M1PUdVI1KGh?		MWDJcoR2[2W\|IFnMMVghemWuZXHz[S=>	NWHLTpZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3PVE1PzdpPkK1O\|kyPDd5PD;hQi=>
U937	MYnGeY5kfGmxbjDBd5NigQ>?	NW\hcmllOTByIH7N	Mm\NOkBp		NUn4U4ZmUW6mdXPld{BKVC16IHX4dJJme3Orb36gbY4hVFCVLYP0bY12dGG2ZXSgWVk{PyCvYXPyc5Bp[Wencx?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd7MUS3O{c,OjV5OUG0O\|c9N2F-
HH	NHiwWYZOcWe{YYTpc44hSXO\|YYm=	MWGxNFAhdk1?	NYDoW4N3OjRiaB?=	MlTjSG1UVw>?	NWLjcYt3WmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mxKS=>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ6MUOzOUc,OjV4OEGzN\|U9N2F-
Hut-78	NUexR29pVWmpcnH0bY9vKEG\|c3H5	MnexNVAxKG6P	MXGyOEBp	MnLSSG1UVw>?	NWnIXJpyWmWmdXPld{Bk\WyuIH3p[5JifGmxbjDifUA5OOLCk{mwKS=>	MlXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OEGzN\|UoRjJ3NkixN\|M2RC:jPh?=
HH	NGW0RphHfW6ldHnvckBCe3OjeR?=	MVixNFAhdk1?	NGjabnMzPCCq	NW\DbpRmTE2VTx?=	M4L0Z4Rwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTJiZYjwdoV{e2mxbh?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ6MUOzOUc,OjV4OEGzN\|U9N2F-
H9	MXHGeY5kfGmxbjDBd5NigQ>?	M4CzclExOCCwTR?=	MUmyOEBp	NWXVOlB3TE2VTx?=	NGTYd\|VFd3ewcnXneYxifGW\|IGTHSk3PujFiYX7kJGlNNTFzIHX4dJJme3Orb36=	NVvJdYkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2PFE{OzVpPkK1OlgyOzN3PD;hQi=>
Hut-78	Mn24SpVv[3Srb36gRZN{[Xl?	NXOzSGFwOTByIH7N	MWKyOEBp	M3noWmROW09?	M{PDbWRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?=	Ml\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV4OEGzN\|UoRjJ3NkixN\|M2RC:jPh?=
H1299	MmLVRZBweHSxc3nzJGF{e2G7	M4q0TlgxKG6P	NXy4NI52OjRiaB?=	NVOwTVdZTE2VTx?=	M4qyVXNmdnOrdHn6[ZMhVlOFTFOgZ4VtdHNidH:gUXNENWSncnn2[YQhcUN7LXnu[JVk\WRiYYDvdJRwe2m\|	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN{M{[5N{c,OjV\|MkO2PVM9N2F-
BLM	NWG0NZlmSXW2b4DoZYd6KEG\|c3H5	MkfaNVAhdk1?	NHm2[GMyOiCq		Ml;QTY5lfWOnczDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO=	MnT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyN{mwPFMoRjJ\|MEe5NFg{RC:jPh?=
A375	MYrBeZRweGijZ4mgRZN{[Xl?	Ml\tNVAhdk1?	M1jmVlEzKGh?		NG\aXYZKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:\|b33ldy=>	NHHTflM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C3PVA5Oyd-MkOwO\|kxQDN:L3G+
BLM	MlmxRZBweHSxc3nzJGF{e2G7	MlrWNVAhdk1?	NV;OO4ZHOjRiaB?=		MlTaTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NHjjeYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{C3PVA5Oyd-MkOwO\|kxQDN:L3G+
A375	MmrYRZBweHSxc3nzJGF{e2G7	M3;yblExKG6P	NH3WcYczPCCq		MUfJcoR2[2W\|IHPlcIwh[XCxcITvd4l{	M{DtWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEe5NFg{Lz5{M{C3PVA5OzxxYU6=
RAW 264.7	NGfBWZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkW3NVAxKG6P	MnTHOFghcA>?		NVHaSmp1WmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	NF;hNY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkSyO\|E2PCd-MkK0NlcyPTR:L3G+
SNK-6	Mm\1RY51cX[rcnHsJGF{e2G7	MoHiNUDPxE1?	MV6yOEBp		NIDCPFhKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ?	NF3qWG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3NFk5QCd-MkGxO\|A6QDh:L3G+
KAI-3	NWjJ[Y1kSW62aY\pdoFtKEG\|c3H5	NFjSOFIyKM7:TR?=	M371RVI1KGh?		NGe5TolKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ?	NXfOZ49zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|A6QDhpPkKxNVcxQTh6PD;hQi=>
SNT-16	MVnBcpRqfmm{YXygRZN{[Xl?	M3i3cVEh\|ryP	MVOyOEBp		MmTCTY5lfWOnczDsfZRq[yCrbn\lZ5Rqd25ib3[gSWJX	NIi1cFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3NFk5QCd-MkGxO\|A6QDh:L3G+
SNT-13	NVjPXFZ5SW62aY\pdoFtKEG\|c3H5	MXqxJO69VQ>?	MVqyOEBp		NILyUmtKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
KHYG-1	NXfKcXlZSXCxcITvd4l{KEG\|c3H5	NX;LdWI{OSEQvF2=	MYO2JIg>		MWLJcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NYjycGZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|A6QDhpPkKxNVcxQTh6PD;hQi=>
KAI-3	MlLrRZBweHSxc3nzJGF{e2G7	MV[xJO69VQ>?	NWX0bmVtPiCq		NYDtZYQ6UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	Mo[wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzN{C5PFgoRjJzMUewPVg5RC:jPh?=
Jurkat	MnvGRZBweHSxc3nzJGF{e2G7	NXqzc4RUOSEQvF2=	NU\jVJl{PiCq		NF7QNlFKdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
SNT-16	M3rRWWFxd3C2b4Ppd{BCe3OjeR?=	MlSxNUDPxE1?	NWn6[25GPiCq		NGHycVhKdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NFy1Um89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3NFk5QCd-MkGxO\|A6QDh:L3G+
KHYG-1	M13kSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXIXJUyKM7:TR?=	NEPwRoQzPCCq		NXfwUFZzWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	M3PCWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUewPVg5Lz5{MUG3NFk5QDxxYU6=
SNK-6	MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HEPVEh\|ryP	NV7iSm5sOjRiaB?=		MUPS[YR2[2W\|IHPlcIwhfmmjYnnsbZR6yqB?	M4TLN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUewPVg5Lz5{MUG3NFk5QDxxYU6=
KAI-3	NGS0bFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXqxJO69VQ>?	Moq2NlQhcA>?		MXnS[YR2[2W\|IHPlcIwhfmmjYnnsbZR6yqB?	M{LnS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUewPVg5Lz5{MUG3NFk5QDxxYU6=
Jurkat	NYGxepJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nwWVEh\|ryP	M4DlZ\|I1KGh?		M{LCcHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	M2DrZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMUewPVg5Lz5{MUG3NFk5QDxxYU6=
SNT-16	NYPKZ\|lCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn75NUDPxE1?	M1H5XlI1KGh?		MWLS[YR2[2W\|IHPlcIwhfmmjYnnsbZR6yqB?	MnPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFzN{C5PFgoRjJzMUewPVg5RC:jPh?=
SNT-13	MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{[5[VEh\|ryP	MmjlNlQhcA>?		MnHnVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi	NIC4cY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3NFk5QCd-MkGxO\|A6QDh:L3G+
BJAB	M{XJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTMRW4yKM7:TR?=	M4DmNlI1KGh?		NUP0NHgyWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg	NHjpfWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG3NFk5QCd-MkGxO\|A6QDh:L3G+
LCL-2	Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jqblEh\|ryP	NV7qU21TOjRiaB?=		M2DEcnJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
LCL-1	M4\aNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fJeVEh\|ryP	MWiyOEBp		NHX6SGxT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=	NUjmO\|Z5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGxO\|A6QDhpPkKxNVcxQTh6PD;hQi=>
Raji	M13zUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnReZlNOSEQvF2=	MUCyOEBp		MmH0VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF5MEm4PEc,OjFzN{C5PFg9N2F-
BaF/3-p210	MVjGeY5kfGmxbjDBd5NigQ>?	M{ixclYhdk1?	MWqyOEBp		NVfsdXh6WmWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKGGwZDD0bIUh[WO2aY\peJkhd2ZiUnK=	MlfGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|MEW2PVIoRjJyM{C1OlkzRC:jPh?=
BaF/3-p210	Mnj3SpVv[3Srb36gRZN{[Xl?	MY[2JI5O	NVHtOnVwPDhiaB?=		NFHTO5pKdmS3Y3XzJIEhe2yrZ3j0JGcyKGOnbHytZ5lkdGViYYLy[ZN1	M{WxU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{C1OlkzLz5{MEOwOVY6OjxxYU6=
BaF/3	M3nKNmZ2dmO2aX;uJGF{e2G7	M4K1ZVYhdk1?	MX20PEBp		Mni1TY5lfWOnczDhJIdz\WG2IFexJINmdGxvY4njcIUh[XK{ZYP0	NUHNUnJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzNFU3QTJpPkKwN\|A2Pjl{PD;hQi=>
TCC-S	M1PP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLWNVAxKG6P	MkXXOFghcA>?		M{PpbWlEPTB;Mj64JI5O	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODNyNU[5Nkc,OjB\|MEW2PVI9N2F-
BaF/3-p210	M1\KSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDCV3BqOTByIH7N	MUC0PEBp		NEPq[YtKSzVyPUSuO{BvVQ>?	Mn6xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|MEW2PVIoRjJyM{C1OlkzRC:jPh?=
BaF/3	NGPDc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVSxNFAhdk1?	NXjRZ3ZPPDhiaB?=		M365[2lEPTB;Nj6yJI5O	NIXWZ289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEOwOVY6Oid-MkCzNFU3QTJ:L3G+
RPMI 8226	NEO5ZWZHfW6ldHnvckBCe3OjeR?=	NE\kTJUzOCCwTR?=	NXSxNYdTQCCq		NVHRNFg2UW6mdXPld{BFVkFic4nueIhme2m\|	M{jZdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NEO2NFUxLz5zOUSzOlA2ODxxYU6=
OPM2	M4TuVWZ2dmO2aX;uJGF{e2G7	M{Dj[FIxKG6P	M2i3UFghcA>?		M3f4[3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	NUDUenZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0N\|YxPTBpPkG5OFM3ODVyPD;hQi=>
INA6	MlP3SpVv[3Srb36gRZN{[Xl?	NUf6fnEzOjBibl2=	MV64JIg>		NGLDZWtUcWewaX\pZ4FvfGy7IHXubIFv[2W\|IF7GMe67SiCjY4Tpeol1gQ>?	NH6wVI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUSzOlA2OCd-MUm0N\|YxPTB:L3G+
OPM1	NEf0eZBHfW6ldHnvckBCe3OjeR?=	NHPm[o8zOCCwTR?=	MX[4JIg>		M2fVbXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	Ml:zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2M{[wOVAoRjF7NEO2NFUxRC:jPh?=
U266	MkjSSpVv[3Srb36gRZN{[Xl?	MmfLNlAhdk1?	MVi4JIg>		M1;YOXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	Mo[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl2M{[wOVAoRjF7NEO2NFUxRC:jPh?=
MM.1S	MoTwSpVv[3Srb36gRZN{[Xl?	MorwNlAhdk1?	NWOycFRNQCCq		NYHrfo1JW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR\|NkC1NEc,OTl2M{[wOVA9N2F-
RPMI 8226	MoC3SpVv[3Srb36gRZN{[Xl?	M3zUXVIxKG6P	NWnUd\|dmQCCq		M4jZcXNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6	NWHlOXdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0N\|YxPTBpPkG5OFM3ODVyPD;hQi=>
CHLA-255	MmLRSpVv[3Srb36gRZN{[Xl?	NFPwbGwyOCCwTR?=	MXqyOEBp		NEnQdY9Od2Snc4TsfUBz\WS3Y3XzJINmdGy\|IHnuJJRp\SCJMD;HNUBxcGG\|ZR?=	NW\4XmR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2PFk3QDRpPkG3Olg6Pjh2PD;hQi=>
NB-1691	NH:4eoFHfW6ldHnvckBCe3OjeR?=	MVmxNEBvVQ>?	MlfXNlQhcA>?		M{jT[XNq\26rZnnjZY51dHlicnXkeYNmeyClZXzsd{BqdiC2aHWgS\|AwTzFicHjhd4U>	NYH0NplVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2PFk3QDRpPkG3Olg6Pjh2PD;hQi=>
SK-N-AS	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\pNUDPxE1?	M33ZWFczKGh?		MUHJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOTBn	MofiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4OEm2PFQoRjF5Nki5Olg1RC:jPh?=
CHLA-255	Mn3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHkNUDPxE1?	M2[0N\|czKGh?		NGf1TZJKdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hfG9iMjW=	NWPocXNFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe2PFk3QDRpPkG3Olg6Pjh2PD;hQi=>
NB-1691	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfoVYQyKM7:TR?=	M1jJZlczKGh?		MVzJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hPSV?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ6OU[4OEc,OTd4OEm2PFQ9N2F-
HKe-3	MVvBdI9xfG:\|aYOgRZN{[Xl?	MV21NEBvVQ>?	NVHD[Gp2PDhiaB?=	Ml;KSG1UVw>?	NGL1XHRKdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NIDwZo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNke3PFE4QSd-MU[3O\|gyPzl:L3G+
HCT116	MXXBdI9xfG:\|aYOgRZN{[Xl?	MkjvOVAhdk1?	NH7jeXM1QCCq	NFzoPVNFVVOR	NVHrcppnUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd5OEG3PUc,OTZ5N{ixO\|k9N2F-
T29Kt1	NXOzRWRuSXCxcITvd4l{KEG\|c3H5	MWW1NEBvVQ>?	MX20PEBp	NIPvN3BFVVOR	M1fiTWlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd5OEG3PUc,OTZ5N{ixO\|k9N2F-
T29	NVTpWJlnSXCxcITvd4l{KEG\|c3H5	MXO1NEBvVQ>?	NVzKb4tVPDhiaB?=	NFzxSWhFVVOR	NWPrUHk5UW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NWnGS2RHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[3O\|gyPzlpPkG2O\|c5OTd7PD;hQi=>
LNCap-Pro5	Mnm0SpVv[3Srb36gRZN{[Xl?	MnHMNUDPxE1?	NF[xcY41KGh?	NVTNWVI3TE2VTx?=	MWfTeIFjcWyrenXzJJA2Ow>?	NHjrZWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNE[xNlU{Oid-MUS2NVI2OzJ:L3G+
H460	MnvrSpVv[3Srb36gRZN{[Xl?	MW[xNFAhdk1?	MlHZNlQhcA>?	MV3EUXNQ	M1TydWlv\HWlZYOgS\|IuVS2yaHHz[UBienKnc4SgZY5lKHS3YoXsbY4h[XO\|ZX3icJku\Gm\|YYPz[Y1jdHl?	M4PPb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NkOxOlIxLz5zMk[zNVYzODxxYU6=
H322	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW[xNEDPxE1?	M4j5ZVczKGh?	NHyxd3dFVVOR	MXTJR\|UxRTZ{MDDuUS=>	MoTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ4M{G2NlAoRjF{NkOxOlIxRC:jPh?=
H358	NGHweHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXGxNEDPxE1?	NX;zU21OPzJiaB?=	Mlr5SG1UVw>?	NH\0XndKSzVyPUewJI5O	NX\kR2pFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2N\|E3OjBpPkGyOlMyPjJyPD;hQi=>
H460	NIjU[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX[xNEDPxE1?	Mn21O\|IhcA>?	MojqSG1UVw>?	M1TkbGlEPTB;MUCwJI5O	NEHIOpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[zNVYzOCd-MUK2N\|E3OjB:L3G+
RPMI8226/LR5	NYPnemFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn:3OVAxKG6pL33s	M2ftTlQ5KGh?	MXXEUXNQ	M4XFO2lvcGmkaYTzJINmdGxiZ4Lve5Rp	NWC2S\|h6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2N\|E3OTlpPkGyOlMyPjF7PD;hQi=>
U266/dox4	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEP2dFU2ODBibnevcYw>	MWm0PEBp	Mli3SG1UVw>?	NInsc4pKdmirYnn0d{Bk\WyuIHfyc5d1cA>?	MnjjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ4M{G2NVkoRjF{NkOxOlE6RC:jPh?=
U266/LR7	NFXHbXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHZSmVNPTByIH7nM41t	MmnwOFghcA>?	MlTiSG1UVw>?	MmmxTY5pcWKrdIOgZ4VtdCCpcn;3eIg>	NXW1UoJFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK2N\|E3OTlpPkGyOlMyPjF7PD;hQi=>
WAD-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVW1NFAhdmdxbXy=	NHnIS5U1QCCq	M1fx[WROW09?	Mkn3TY5pcWKrdIOgZ4VtdCCpcn;3eIg>	MnflQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ4M{G2NVkoRjF{NkOxOlE6RC:jPh?=
ARH77	M3fhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvUdGs2ODBibnevcYw>	M4f4ZlQ5KGh?	NH\QWlFFVVOR	MUfJcohq[mm2czDj[YxtKGe{b4f0bC=>	NFWwRnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[zNVYyQSd-MUK2N\|E3OTl:L3G+
U266	M1L3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTuOVAxKG6pL33s	NELtVVM1QCCq	MkLUSG1UVw>?	M4TIbGlvcGmkaYTzJINmdGxiZ4Lve5Rp	NIL4VZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMk[zNVYyQSd-MUK2N\|E3OTl:L3G+
H460	MUXGeY5kfGmxbjDBd5NigQ>?	NE\wfXIyOCEQvF2=	NG\JTJIzPCCq	NHzncY9FVVOR	MVPJcoR2[2W\|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1	NYHhVIRrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK0PVIyOTdpPkGyOFkzOTF5PD;hQi=>
UM-SCC-11B	MnPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVewU5J2OTByIH7N	MXW3NkBp	NI\qSJVFVVOR	Mnj0TY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTN3MEmxN{c,OTF\|NUC5NVM9N2F-
UM-SCC-9	M2q0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4WyXFExOCCwTR?=	NGDEUoI4OiCq	NUDJVYRmTE2VTx?=	NXHWOGhjUW6qaXLpeJMh[2WubDD2bYFjcWyrdIm=	NXfFdmU2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzOVA6OTNpPkGxN\|UxQTF\|PD;hQi=>
B7E3	NEPiV\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVOxNFAhdk1?	MV:3NkBp	NYW5PIhOTE2VTx?=	NH;2eJJKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=	MnnvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF\|NUC5NVMoRjFzM{WwPVE{RC:jPh?=
B4B8	NWf3Z444T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXrR4oyODBibl2=	NILFZoY4OiCq	NF;oPIFFVVOR	NGrJSoRKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=	NWHlbIhiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzOVA6OTNpPkGxN\|UxQTF\|PD;hQi=>
PAM-LY2	M2jvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHJNVAxKG6P	MVW3NkBp	Mk\zSG1UVw>?	M3TxZ2lvcGmkaYTzJINmdGxidnnhZoltcXS7	M4PPeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{WwPVE{Lz5zMUO1NFkyOzxxYU6=
PAM 212	NYfRfolpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jSOlExOCCwTR?=	Mn7JO\|IhcA>?	MVHEUXNQ	NEG0[ItKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=	NITH[3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUO1NFkyOyd-MUGzOVA6OTN:L3G+
PAM-LY2	NIDOZm9HfW6ldHnvckBCe3OjeR?=	MkPhNVAxKG6P	MVGxNkBp	M3fHbGROW09?	NEfDbnNKdmirYnn0d{BPTi4QulKgZYN1cX[jdHnvci=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTN3MEmxN{c,OTF\|NUC5NVM9N2F-
Hs Sultan	MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrmfIx{OTByIH7N	NYC0ZVNSPDhiaB?=	MlPVSG1UVw>?	NEHXXW5KSzVyPUKwJI5O	NYi3ZoN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzNFY1QDlpPkGxN\|A3PDh7PD;hQi=>
IM-9	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnf0NVAxKG6P	NHnWR5U1QCCq	MUDEUXNQ	MnTYTWM2OD14IH7N	MlHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF\|ME[0PFkoRjFzM{C2OFg6RC:jPh?=
U266	NVjwWlZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY[xNFAhdk1?	NV3LSII{PDhiaB?=	NWH0XWpLTE2VTx?=	M3\MXmlEPTB;MzDuUS=>	NXfyOGQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzNFY1QDlpPkGxN\|A3PDh7PD;hQi=>
LR5	NEm4d2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWGwVIJVOTByIH7N	M1nOTlQ5KGh?	NXKyWXFYTE2VTx?=	NV3YfIxiUUN3ME2yNEBvVQ>?	Mny2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF\|ME[0PFkoRjFzM{C2OFg6RC:jPh?=
MR20	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\YNVAxKG6P	NGPZWHU1QCCq	NXPjTmpMTE2VTx?=	Mn60TWM2OD1{MDDuUS=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTNyNkS4PUc,OTF\|ME[0PFk9N2F-
Dox40	M1KzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXqxNFAhdk1?	M{iyVFQ5KGh?	MYfEUXNQ	MWPJR\|UxRTRyIH7N	M1WwTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{C2OFg6Lz5zMUOwOlQ5QTxxYU6=
RPMI8226	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XaWlExOCCwTR?=	M1PmeFQ5KGh?	NYTOfo9ZTE2VTx?=	MnPqTWM2OD1\|MDDuUS=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTNyNkS4PUc,OTF\|ME[0PFk9N2F-
OVCA 429	Mnm2SpVv[3Srb36gRZN{[Xl?	MmjtN\|AxKG6P	NIH4UGM1QCCq	M4rlWmROW09?	Mom3SIl{enWydIOgbY51[WO2IH31cJRq[2WubIXsZZIhfHWvb4Kgd5Bp\XKxaXTz	NH\C[ow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEm5PVc3Pid-MUC5PVk4PjZ:L3G+
MCF-7	MlvaR5l1d3SxeHnjJGF{e2G7	MlrEOVAh\|ryP	M1myWFQ5KGh?	NVLNc4RUTE2VTx?=	MnHsT4ltdHNiY3XscJMh[nlibX;y[UB1cGGwIEm5KS=>	M3jlZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyNEm5OlQ{Lz5zMES5PVY1OzxxYU6=
FSCLL	M1PoUmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NXrOdpNnOjRiaILz		NGriNm1ESzVyIE2gNE4xODRizszN	NHj0[Jk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MU[zOFQzQSd-MkG2N\|Q1Ojl:L3G+
HEK293	NYXkUYdqS3m2b4TvfIlkcXS7IHHzd4F6		NHvUcG8zPCCqcoO=		M{S3T2NEPTBiPTCwMlM1PyEQvF2=	NYLZOWNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2N\|Q1OjlpPkKxOlM1PDJ7PD;hQi=>
Glioma (HF2303)	MlPxR5l1d3SxeHnjbZR6KGG\|c3H5		MmLOO\|IhcHK\|		MYnFR\|UxKD1iMD6wNFA4KM7:TR?=	M1PPZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mki4Olk6Lz5{NkK4PFY6QTxxYU6=
Glioma (HF2476)	NE[zdYJEgXSxdH;4bYNqfHliYYPzZZk>		M2joZlczKGi{cx?=		NH[1dHRGSzVyIE2gNE4xODB5IN88US=>	NUTnUFI1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPFg3QTlpPkK2Nlg5Pjl7PD;hQi=>
Glioma (HF2876)	MX3DfZRwfG:6aXPpeJkh[XO\|YYm=		NEHUO4c4OiCqcoO=		M13EPGVEPTBiPTCwMlAxODdizszN	NX\Zd2dzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPFg3QTlpPkK2Nlg5Pjl7PD;hQi=>
Glioma (HF2885)	NY\INmJFS3m2b4TvfIlkcXS7IHHzd4F6		MYO3NkBpenN?		M2jrbWVEPTBiPTCwMlAxODdizszN	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ6OE[5PUc,OjZ{OEi2PVk9N2F-
Glioma (HF3013)	Mo\XR5l1d3SxeHnjbZR6KGG\|c3H5		MlrnO\|IhcHK\|		NYeyenpsTUN3MDC9JFAvODByNzFOwG0>	NVjUS3RFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yPFg3QTlpPkK2Nlg5Pjl7PD;hQi=>
Glioma (HF2381)	MXXDfZRwfG:6aXPpeJkh[XO\|YYm=		MYe3NkBpenN?		MUTFR\|UxKD1iMD6wNFA4KM7:TR?=	NEfGOnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK4PFY6QSd-Mk[yPFg3QTl:L3G+
Glioma (HF2790)	NWjEZYZvS3m2b4TvfIlkcXS7IHHzd4F6		NXfTfZRpPzJiaILz		MWrFR\|UxKD1iMD6wNFA4KM7:TR?=	MmjJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{OEi2PVkoRjJ4Mki4Olk6RC:jPh?=
HepG2	Ml;lR5l1d3SxeHnjbZR6KGG\|c3H5		M{TNPVQ5KGi{cx?=		M2DXe2VEPTBiPTCwMlAyKM7:TR?=	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQThyMEiyO{c,Ojl6MEC4Nlc9N2F-
Molt4	MkfBSpVv[3Srb36gZZN{[Xl?				MYLFR\|UxKD1iMD6wNlEh\|ryP	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDJ2N{W0O{c,OTh{NEe1OFc9N2F-
Molt4	MXTGeY5kfGmxbjDhd5NigQ>?				M1LLfGVEPTBiPTCwMlAzOSEQvF2=	M2rnT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUCzN\|Q6Lz5{MkWwN\|M1QTxxYU6=
HL60	M335TWZ2dmO2aX;uJIF{e2G7		M2fsVFExKG2rboO=		NWTxWnVrTUR3MDC9JFAvODB{NTFOwG0>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR{MkKwOkc,OTl2MkKyNFY9N2F-
HL60	Mmn4SpVv[3Srb36gZZN{[Xl?		NY\SSJZvOTBibXnudy=>		M3HEe2VFPTBiPTCwMlAxOjVizszN	MlTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7N{OxNFEoRjJzOUezNVAyRC:jPh?=
RPMI8226	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MXLHTVUxKD1iMD6wNFAzOyEQvF2=	NWS1ZoNVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
CCRF-CEM	Mn3wS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MX3HTVUxKD1iMD6wNFA{PSEQvF2=	NYXWOZhERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
MDA-MB-435	NVn5WoVNT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MnTFS2k2OCB;IECuNFAxPDRizszN	NF\T[W89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
MALME-3M	Mk\TS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M3z3emdKPTBiPTCwMlAxODR3IN88US=>	M3nBcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
NCI-H226	Mn;0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MYfHTVUxKD1iMD6wNFA1PiEQvF2=	NHvPOmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
SK-MEL-28	MmSxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M4TCSWdKPTBiPTCwMlAxODR4IN88US=>	NHPsZok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
A498	M2C2VGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MULHTVUxKD1iMD6wNFA1QCEQvF2=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
MOLT4	MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MlTOS2k2OCB;IECuNFAxPTFizszN	NIPhS3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
OVCAR3	M1fmTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NWXzVJFtT0l3MDC9JFAvODByNUSg{txO	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
SW620	NF7ZNFFIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MUjHTVUxKD1iMD6wNFA2PSEQvF2=	NHXjWoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
MCF7	NEP5RnpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				M1jrOWdKPTBiPTCwMlAxODV3IN88US=>	NWrwd5lORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
BT549	NXe5NXVGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MmPFS2k2OCB;IECuNFAxPTVizszN	NGTxSGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
UACC257	NWL1[ZBUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NEXz[3pIUTVyIE2gNE4xODB3OTFOwG0>	NYDtWlB1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
SF539	MnjuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M2LkVWdKPTBiPTCwMlAxODV7IN88US=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
HCC2998	MlrRS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MVnHTVUxKD1iMD6wNFA3KM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
HCT116	NXPJ[lQ6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MX7HTVUxKD1iMD6wNFA3KM7:TR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
T47D	Mm\pS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NUDOVIRIT0l3MDC9JFAvODByNjFOwG0>	M2XWeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
CAKI-1	MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M{XSU2dKPTBiPTCwMlAxODZ4IN88US=>	NVzTbnVSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
SK-MEL-5	MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				MWnHTVUxKD1iMD6wNFA3QCEQvF2=	M2jpNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
RXF393	MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				NGG1[GdIUTVyIE2gNE4xODB5MTFOwG0>	NG[yRmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
LOXIMVI	M3zE[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NUXx[mZtT0l3MDC9JFAvODByN{ig{txO	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
ACHN	NHLnTYRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MkfnS2k2OCB;IECuNFAxPzlizszN	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
SR	NUPqSnVJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				M3XSOmdKPTBiPTCwMlAxODh3IN88US=>	NGTYVVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
UACC62	MYLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				Mne2S2k2OCB;IECuNFAxQTFizszN	MnLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
M14	MlXKS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				Mof3S2k2OCB;IECuNFAxQTNizszN	NUPOWZd4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
HT-29	NUjsdmpVT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MmfNS2k2OCB;IECuNFAxQTVizszN	NWTwc2RKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
HOP92	M3\tcmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M4iwNWdKPTBiPTCwMlAxOSEQvF2=	NGPoU3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
NCI-H23	NXP5TJlvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NV;vPYhjT0l3MDC9JFAvODBzIN88US=>	MoTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
TK10	M{[3Umdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M{jR[GdKPTBiPTCwMlAxOSEQvF2=	MnexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
CEM	NVLCU4t[SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3jxZVczKGi{cx?=		NGXzemdIUTVyIE2gNE4xODFizszN	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR2MUW4Nkc,Ojh2NEG1PFI9N2F-
U266	Mk\sRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MV23NkBpenN?		NEfFRYlIUTVyIE2gNE4xODFizszN	M1vSfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NESxOVgzLz5{OES0NVU5OjxxYU6=
Hs 578T	M3LBOGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MVvHTVUxKD1iMD6wNFExOiEQvF2=	NVS0U2hyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
UO31	MkK4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M1;wV2dKPTBiPTCwMlAxOTB3IN88US=>	NFLCSXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
SK-MEL-2	NX;kXmlRT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MV7HTVUxKD1iMD6wNFExPyEQvF2=	NGriVmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
SN12C	MljqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NILOUHlIUTVyIE2gNE4xODFzIN88US=>	NHPpR5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
K562	M2XGUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MkDvS2k2OCB;IECuNFAyOTdizszN	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
SF268	M2TGNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M1f0[mdKPTBiPTCwMlAxOTF5IN88US=>	NG\mbYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
COLO205	MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				Mnm2S2k2OCB;IECuNFAyOjNizszN	NWDa[3h1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
MDA-MB-231	M{PkSGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NXjnWmpPT0l3MDC9JFAvODBzMk[g{txO	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
NCI-H522	M2q0T2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7				M4rqO2dKPTBiPTCwMlAxOTR2IN88US=>	NXezcIJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
786-0	NWX5[WZuT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				M3[yOWdKPTBiPTCwMlAxOTR2IN88US=>	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
MDA-MB-468	NXTIR295T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				NF7l[I5IUTVyIE2gNE4xODF2ODFOwG0>	NIqwSHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
HCT15	MnLVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NUj0fHdVT0l3MDC9JFAvODBzNUGg{txO	NYnEZYN[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
U251	M3\CXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NEHlc3pIUTVyIE2gNE4xODF3NTFOwG0>	M2TPSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
OVCAR5	MnfMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MVHHTVUxKD1iMD6wNFE2PSEQvF2=	M3nPcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
KM12	NFrmblRIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NFr5RlRIUTVyIE2gNE4xODF5IN88US=>	NIXiVIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
SF295	MoPkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				M37mPWdKPTBiPTCwMlAxOTdizszN	Mn6wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
DU145	M{f6[Gdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				MYDHTVUxKD1iMD6wNFE4KM7:TR?=	NIToPXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
HL-60(TB)	M3;2Z2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NWTIdHJ5T0l3MDC9JFAvODBzOTFOwG0>	M3fURlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
OVCAR4	Mm\LS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				MYXHTVUxKD1iMD6wNFE6PSEQvF2=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
SNB19	MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M1fae2dKPTBiPTCwMlAxOjB2IN88US=>	NWTUbVl3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
SNB75	NIfiVHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NXzBVGxkT0l3MDC9JFAvODB{MESg{txO	MmizQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
IGROV1	NITSV3pIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NXPRd\|BIT0l3MDC9JFAvODB{MkSg{txO	NWLRVoltRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
OVCAR8	NFzRb\|RIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				NUH6bmJ{T0l3MDC9JFAvODB{NkOg{txO	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl2NkKxOEc,OjR7NE[yNVQ9N2F-
PC3	M2\i[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NUfiTmNtT0l3MDC9JFAvODB{NkOg{txO	NVLZeplERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
EKVX	MkPpS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				Mn;0S2k2OCB;IECuNFA{ODJizszN	NUjuTZE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFYzOTRpPkK0PVQ3OjF2PD;hQi=>
A549/ATCC	NIfYNpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=				MUXHTVUxKD1iMD6wNFMxQSEQvF2=	NGf0b\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm0OlIyPCd-MkS5OFYzOTR:L3G+
HOP62	NXy5Z3VGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=				MXTHTVUxKD1iMD6wNFQ1PyEQvF2=	MoPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
NCI-H460	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?				M1vBOmdKPTBiPTCwMlAxPDR5IN88US=>	M3XWd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUS2NlE1Lz5{NEm0OlIyPDxxYU6=
K562	M2HURWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MoO2O\|IhcHK\|		M4jG[WdKPTBiPTCwMlAxPyEQvF2=	Mkj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NEG1PFIoRjJ6NESxOVgzRC:jPh?=
NCI-ADR-RES	Mnf6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?				NF3jVlFIUTVyIE2gNE4xOTJ\|IN88US=>	MlzRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
SKOV3	M3q3WGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NX\F[4JkT0l3MDC9JFAvODF\|ODFOwG0>	MknyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
NCI-H322M	M4P2Nmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7				NXPaRnNQT0l3MDC9JFAvODF5ODFOwG0>	MoHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NE[yNVQoRjJ2OUS2NlE1RC:jPh?=
DLD1	NX3xXHFWTnWwY4Tpc44h[XO\|YYm=		NVLISm1GPiCqcoO=		M17VSWlEPTBiPTCwMlAxODJizszN	MnXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{ME[4OlkoRjJ{MkC2PFY6RC:jPh?=
DLD1	MnT5SpVv[3Srb36gZZN{[Xl?		M16xXFYhcHK\|		MV\JR\|UxKD1iMD6wNFA6KM7:TR?=	MoKyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{ME[4OlkoRjJ{MkC2PFY6RC:jPh?=
HCT116	MkT1R5l1d3SxeHnjbZR6KGG\|c3H5		MmL6O\|IhcHK\|		M2i3TmlEPTBiPTCwMlAxOSEQvF2=	M{jqb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkO0NFM6Lz5{OE[zOFA{QTxxYU6=
HCT116	NX7nS3J[SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M2nNUFczKGi{cx?=		MUjJR\|UxKD1iMD6wNFE1KM7:TR?=	NHPOd2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e2PVA{Oyd-Mke3OlkxOzN:L3G+
HepG2	NYj6SpFGSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NFHZS5o4OiCqcoO=		MWjJR\|UxKD1iMD6wNFE3OSEQvF2=	NIS0Zlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e2PVA{Oyd-Mke3OlkxOzN:L3G+
SKOV3	M1XpUWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHXGTHo4OiCqcoO=		NWX2OINqUUN3MDC9JFAvODBzNkKg{txO	NH3N[\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e2PVA{Oyd-Mke3OlkxOzN:L3G+
A2780	M3jG[GN6fG:2b4jpZ4l1gSCjc4PhfS=>				NXfuc4JuUUN3MDC9JFAvODBzNzFOwG0>	NFHkeZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK0O\|U1Pyd-MUiyOFc2PDd:L3G+
DOGUM	MmW2R5l1d3SxeHnjbZR6KGG\|c3H5		NWP3fXR2PzJiaILz		MYLJR\|UxKD1iMD6wNFIh\|ryP	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzB\|MUW5NEc,OjNyM{G1PVA9N2F-
U266	NHnB[mxEgXSxdH;4bYNqfHliYYPzZZk>		MkHIO\|IhcHK\|		MYfJR\|UxKD1iMD6wNFI1PSEQvF2=	M3jXdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUO3O\|E3Lz5zOUWzO\|cyPjxxYU6=
A549	NWLEWZI6SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NUXJOHR3PzJiaILz		NUfhWVNwUUN3MDC9JFAvODB{NTFOwG0>	NGLoU3Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG4Nlk6OCd-MkixPFI6QTB:L3G+
HL60	M1fxTmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NHvnZZM4OiCqcoO=		M{naemlEPTBiPTCwMlAxOzJizszN	MkTaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzOEK5PVAoRjJ6MUiyPVkxRC:jPh?=
RPMI18226	MlPZR5l1d3SxeHnjbZR6KGG\|c3H5		NF3UUHQ4OiCqcoO=		NXjkXWtWUUN3MDC9JFAvODB\|NTFOwG0>	NGC2dms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC3O\|Y5OSd-MkGwO\|c3QDF:L3G+
HL60	M4LFcmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NFr0VVM4OiCqcoO=		MnzhTWM2OCB;IECuNFA{PSEQvF2=	M4TuSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEe3OlgyLz5{MUC3O\|Y5OTxxYU6=
RPMI8226	NF7xWFFEgXSxdH;4bYNqfHliYYPzZZk>		MoH6O\|IhcHK\|		MWLJR\|UxKD1iMD6wNFM5QCEQvF2=	NXK4SZh[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[5OlU5PjdpPkK2PVY2QDZ5PD;hQi=>
HL60	Mn;OSpVv[3Srb36gZZN{[Xl?		Mlr5NkBpenN?		M2n6dGlEPTBiPTCwMlAxPCEQvF2=	NFz4RVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e2PVA{Oyd-Mke3OlkxOzN:L3G+
U266	NEnsXnZHfW6ldHnvckBie3OjeR?=		MVqxJIhz		NYXyZmdzUUN3MDC9JFAvODB2IN88US=>	NFzTcXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES0NVU5Oid-Mki0OFE2QDJ:L3G+
HL60	Mn62SpVv[3Srb36gZZN{[Xl?		MX:yJIhzew>?		NUTJd4RiUUN3MDC9JFAvODB2IN88US=>	MorsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4M{SwN\|koRjJ6NkO0NFM6RC:jPh?=
SEM	M1TTZWZ2dmO2aX;uJIF{e2G7		NHTXRYEzKGi{cx?=		NF7o[odKSzVyIE2gNE4xODR2MzFOwG0>	NXf0d5ZURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOlU5QTJpPkOwN\|Y2QDl{PD;hQi=>
HL60	NYDPdoN4S3m2b4TvfIlkcXS7IHHzd4F6		Mnz4O\|IhcHK\|		MY\JR\|UxKD1iMD6wNFU2KM7:TR?=	NYXMT4lnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1N\|c4OTZpPkG5OVM4PzF4PD;hQi=>
U266	MVrDfZRwfG:6aXPpeJkh[XO\|YYm=		M3;YOFczKGi{cx?=		MoWzTWM2OCB;IECuNFA2PzNizszN	MoHJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7NkW4OlcoRjJ4OU[1PFY4RC:jPh?=
MGC803	M4qzRWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXP6[otOPzJiaILz		M{TkUWlEPTBiPTCwMlAxPTd6MjFOwG0>	M3q0WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{[5NFM{Lz5{N{e2PVA{OzxxYU6=
GUMBUS	NVvwfG5TS3m2b4TvfIlkcXS7IHHzd4F6		MnvTO\|IhcHK\|		MWDJR\|UxKD1iMD6wNFYh\|ryP	MnXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyM{G1PVAoRjJ\|MEOxOVkxRC:jPh?=
ARH77	NWezbWRyS3m2b4TvfIlkcXS7IHHzd4F6		M{WyNFczKGi{cx?=		M3XCVWlEPTBiPTCwMlAxPjB5IN88US=>	NInCcWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nkm2OVg3Pyd-Mk[5OlU5Pjd:L3G+
SW480	M{THfWN6fG:2b4jpZ4l1gSCjc4PhfS=>		Mo[5O\|IhcHK\|		NUH3N4R3UUN3MDC9JFAvODB4MTFOwG0>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF3OEG4OEc,OjBzNUixPFQ9N2F-
MDA-MB-231	NFzydZRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M2\JeVczKGi{cx?=		NVTRTWVlUUN3MDC9JFAvODB4NTFOwG0>	M1nyfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUiyPVkxLz5{OEG4Nlk6ODxxYU6=
HL60	M4j6UmZ2dmO2aX;uJIF{e2G7		M1;sTlIhcHK\|		M4fZfmlEPTBiPTCwMlAxPjZ5IN88US=>	NHTmbWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEO2OVg6Oid-M{CzOlU5QTJ:L3G+
A549	NX\qTXdFS3m2b4TvfIlkcXS7IHHzd4F6		M1z6flczKGi{cx?=		Mk[xTWM2OCB;IECuNFA3PyEQvF2=	M{L0eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUW4NVg1Lz5{MEG1PFE5PDxxYU6=
RPMI8226	NVXJXGZPSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGPZWYk4OiCqcoO=		M2jXPWlEPTBiPTCwMlAxPjdizszN	M3XEcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MUiyPVkxLz5{OEG4Nlk6ODxxYU6=
5TGM1	MXXDfZRwfG:6aXPpeJkh[XO\|YYm=		MnHMOFghfG9iN{KgbJJ{		M3flOmlEPTBiPTCwMlAxPjd6IN88US=>	Mn3PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzMUm1OVkoRjJ2MUG5OVU6RC:jPh?=
HL60	NU\jOGl2S3m2b4TvfIlkcXS7IHHzd4F6		NXXqdY45PzJiaILz		NH65WW1KSzVyIE2gNE4xODZ7IN88US=>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd2N{izNkc,OTl5NEe4N\|I9N2F-
PC3	NIrLemREgXSxdH;4bYNqfHliYYPzZZk>		MmHyO\|IhcHK\|		M4jHWmlEPTBiPTCwMlAxPyEQvF2=	M{XCc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUW4NVg1Lz5{MEG1PFE5PDxxYU6=
DOGUM	MUXDfZRwfG:6aXPpeJkh[XO\|YYm=		M33hZ\|czKGi{cx?=		M3LQNWlEPTBiPTCwMlAxPyEQvF2=	NUHuN2hVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOwN\|E2QTBpPkKzNFMyPTlyPD;hQi=>
HL60	NX2xeGJwS3m2b4TvfIlkcXS7IHHzd4F6		M130SVczKGi{cx?=		MXHJR\|UxKD1iMD6wNFcyKM7:TR?=	NVy1NmJ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOVgyQDRpPkKwNVU5OTh2PD;hQi=>
MKN45	NY\XelRnSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NYP2cHRZPzJiaILz		MlvhTWM2OCB;IECuNFA4OTVizszN	NHiyOIw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e2PVA{Oyd-Mke3OlkxOzN:L3G+
HepG2	NE\DXWVEgXSxdH;4bYNqfHliYYPzZZk>		MWS3NkBpenN?		M3TFV2lEPTBiPTCwMlAxPzVizszN	NGrlV2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG1PFE5PCd-MkCxOVgyQDR:L3G+
HL60	M{S3WmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1z4N\|czKGi{cx?=		NEPzV2ZKSzVyIE2gNE4xODd4IN88US=>	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd4OUCzN{c,Ojd5NkmwN\|M9N2F-
RPMI8226	NInLbGVEgXSxdH;4bYMh[WO2aY\peJkh[WejaX7zeEBpfW2jbh?=		MofKO\|IhcHK\|		NHLTWWxKSzVyIE2gNE4xODd7NjFOwG0>	MnjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5Nke4NVgoRjJ2N{[3PFE5RC:jPh?=
HL60	MmL0R5l1d3SxeHnjbZR6KGG\|c3H5		NXfYb3NVPzJiaILz		NYL4VmliUUN3MDC9JFAvODB6IN88US=>	Ml;RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4M{SwN\|koRjJ6NkO0NFM6RC:jPh?=
MGC803	NILrU5FEgXSxdH;4bYNqfHliYYPzZZk>		M3;5eFczKGi{cx?=		Mn\uTWM2OCB;IECuNFA5KM7:TR?=	M{\S[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkO0NFM6Lz5{OE[zOFA{QTxxYU6=
SKOV3/TR	MYDGeY5kfGmxbjDhd5NigQ>?		M3iyZ\|Qh\GG7cx?=		M1\RVmlEPTBiPTCwMlAxQCEQvF2=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTd4N{m3N{c,Ojl5Nke5O\|M9N2F-
PC3	NIq2T2FEgXSxdH;4bYNqfHliYYPzZZk>		MXG3NkBpenN?		MVLJR\|UxKD1iMD6wNFg{KM7:TR?=	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB5N{[4NUc,OjFyN{e2PFE9N2F-
U266	NFTOUIdEgXSxdH;4bYNqfHliYYPzZZk>		MmXlO\|IhcHK\|		NEfseIZKSzVyIE2gNE4xODh6IN88US=>	MlXlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNUixPFQoRjJyMUW4NVg1RC:jPh?=
RPMI8226	MmfNR5l1d3SxeHnjbZR6KGG\|c3H5				MYTJR\|UxKD1iMD6wNFg5KM7:TR?=	MmSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB5Mke3OFYoRjJyN{K3O\|Q3RC:jPh?=
RPMI8226	M3;vT2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MYK0PEB1dyB5MjDodpM>		NF\ZZ5pKSzVyIE2gNE4xODl3IN88US=>	M{LNd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUG5OVU6Lz5{NEGxPVU2QTxxYU6=
ARH77	NUflU\|RwS3m2b4TvfIlkcXS7IHHzd4F6		M3;lN\|czKGi{cx?=		MlLxTWM2OCB;IECuNFA6PTdizszN	MnTIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl7M{SyNVgoRjJ7OUO0NlE5RC:jPh?=
HEK293	MYTGeY5kfGmxbjDhd5NigQ>?		NUmwdHgzOyCqcoO=		Ml;2TWM2OCB;IECuNFEh\|ryP	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh5NUezPUc,OjB6N{W3N\|k9N2F-
HCT116	NYLhfpRLS3m2b4TvfIlkcXS7IHHzd4F6		NWTGOZc6PzJiaILz		NUPFb4N2UUN3MDC9JFAvODFizszN	Ml3JQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NEe3OVcoRjJ\|NUS3O\|U4RC:jPh?=
NCI-H929	NH3kVotEgXSxdH;4bYNqfHliYYPzZZk>		MlXSO\|IhcHK\|		NELK[4dKSzVyIE2gNE4xOTB6NTFOwG0>	NFXCNZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe2O\|gyQCd-MkS3Olc5OTh:L3G+
CCRF-CEM	MlvyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3n6OVczKGi{cx?=		NYi3bZBYUUN3MDC9JFAvODFzIN88US=>	NGHoZmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzNVE3Oid-Mk[yN\|EyPjJ:L3G+
RPMI8226	NWOxfXNbS3m2b4TvfIlkcXS7IHHzd4F6		NYK2V3pEPzJiaILz		MoewTWM2OCB;IECuNFEyOiEQvF2=	M3PsWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OUO0NlE5Lz5{OUmzOFIyQDxxYU6=
U266B1	MYfDfZRwfG:6aXPpeJkh[XO\|YYm=		NGD1RZQ4OiCqcoO=		NGTqPZdKSzVyIE2gNE4xOTF4MzFOwG0>	NIjGelU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUmzOFIyQCd-Mkm5N\|QzOTh:L3G+
BxPC3	MkHYR5l1d3SxeHnjbZR6KGG\|c3H5		NGr5TpM4OiCqcoO=		MVjJR\|UxKD1iMD6wNVE5KM7:TR?=	NHHadZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0O\|g{Oid-MUm3OFc5OzJ:L3G+
293T	M2HyVGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYPJW\|BHPzJiaILz		NWThWo9GUUN3MDC9JFAvODF{IN88US=>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDF7MUi1NEc,OjhzOUG4OVA9N2F-
U266	NVLpfZhHS3m2b4TvfIlkcXS7IHHzd4F6		M1XQV\|czKGi{cx?=		MYTJR\|UxKD1iMD6wNVIzKM7:TR?=	M33XdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{S3PFMzLz5zOUe0O\|g{OjxxYU6=
SW480	Mk\lR5l1d3SxeHnjbZR6KGG\|c3H5		NV7USY1SPzJiaILz		NXfHfG1sUUN3MDC9JFAvODF{MzFOwG0>	M4Ls[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEe3OlgyLz5{MUC3O\|Y5OTxxYU6=
SKOV3	M{i4bGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M{XZWlQh\GG7cx?=		MoP3TWM2OCB;IECuNFEzQSEQvF2=	NFvmNoU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe2O\|k4Oyd-Mkm3Olc6PzN:L3G+
A549	NVXFOmtUS3m2b4TvfIlkcXS7IHHzd4F6		MkjGO\|IhcHK\|		NVzZRYdzUUN3MDC9JFAvODF\|OTFOwG0>	M{LEdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEe3OlgyLz5{MUC3O\|Y5OTxxYU6=
HEK293	MXXGeY5kfGmxbjDhd5NigQ>?		MVSzNEBucW6\|		MlrTTWM2OCB;IECuNFE1KM7:TR?=	NInQ[mk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUC0OFg1Pyd-MkGwOFQ5PDd:L3G+
RPMI8266	MV3BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWq3NkBpenN?		MVzJR\|UxKD1iMD6wNVQ1KM7:TR?=	NELpdWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzNVE3Oid-Mk[yN\|EyPjJ:L3G+
BxPC3	NVnoUJhRS3m2b4TvfIlkcXS7IHHzd4F6		NWj0cI1EPzJiaILz		MmrXTWM2OCB;IECuNFE3OiEQvF2=	M4q3fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUW4NVg1Lz5{MEG1PFE5PDxxYU6=
MDA-MB-231	MoXiRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NVPB[IFHPzJiaILz		NW\vd4l3UUN3MDC9JFAvODF4NkWg{txO	NYrVZ3JxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3OlkxOzNpPkK3O\|Y6ODN\|PD;hQi=>
TOV21G	NFGzU\|dCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NH;k[2k4OiCqcoO=		NGf4ZYJKSzVyIE2gNE4xOTZ5IN88US=>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ\|MUG2Nkc,OjZ{M{GxOlI9N2F-
MDA-MB-231	M4rCZmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NHjWeXQ4OiCqcoO=		M{W2NmlEPTBiPTCwMlAyPyEQvF2=	MmjiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4M{SwN\|koRjJ6NkO0NFM6RC:jPh?=
BxPC3	MWLDfZRwfG:6aXPpeJkh[XO\|YYm=		NGnvT3Q4OiCqcoO=		MX\JR\|UxKD1iMD6wNVk1KM7:TR?=	MoH6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjFyN{e2PFEoRjJzMEe3OlgyRC:jPh?=
HeLa	NH:0S3dIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NWLleFE2PzJiaILz		MVXJR\|UxKD1iMD6wNkDPxE1?	NI\5R4o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUSyPFI1PSd-MUm0NlgzPDV:L3G+
RKO	NUL0TY5sSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MXu3NkBpenN?		NE\wdHRKSzVyIE2gNE4xOjB6IN88US=>	NHHZSGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzNVE3Oid-Mk[yN\|EyPjJ:L3G+
MCF7	MmDCRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NE\hRVM{KGSjeYO=		Mor2TWM2OCB;IECuNFI2KM7:TR?=	NInrNJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEW1O\|Q{OCd-Mki1OVc1OzB:L3G+
Bel7404	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mn\6O\|IhcHK\|		MlzrTWM2OCB;IECuNFI2ODRizszN	NVnSZZZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3OlkxOzNpPkK3O\|Y6ODN\|PD;hQi=>
HepG2	NH3wbmdEgXSxdH;4bYNqfHliYYPzZZk>		MnvMO\|IhcHK\|		NF7M[IxKSzVyIE2gNE4xOjV{IN88US=>	NWDGT5dLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwO\|c3QDFpPkKxNFc4PjhzPD;hQi=>
HEK293	NETXXmtHfW6ldHnvckBie3OjeR?=		MWKyOEBpenN?		M37O[GlEPTBiPTCwMlAzPyEQvF2=	M{HVdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkO0OFI6Lz5{MU[zOFQzQTxxYU6=
HCT116	M4ryUWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWq3NkBpenN?		M4\JNmlEPTBiPTCwMlAzPyEQvF2=	NH3U[Ic9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKzNVE3Oid-Mk[yN\|EyPjJ:L3G+
SUP-B15	Mlq1SpVv[3Srb36gZZN{[Xl?		NF\qTJkzKGi{cx?=		MVLJR\|UxKD1iMD6wNlgxQSEQvF2=	M{XEb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyM{[1PFkzLz5\|MEO2OVg6OjxxYU6=
A431	M3XV[mFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NEL6fY44OiCqcoO=		M2S5S2lEPTBiPTCwMlAzQDJizszN	NVf0SpFsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[yN\|EyPjJpPkK2NlMyOTZ{PD;hQi=>
A2780	NXS0cm01SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NFTGU4Q4OiCqcoO=		M3fsbmlEPTBiPTCwMlAzQDlizszN	NWfpZpB5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkixPFI6QTBpPkK4NVgzQTlyPD;hQi=>
HL60	M2n4OWZ2dmO2aX;uJIF{e2G7		NXL5ZnVpOiCqcoO=		NFnDbnVKSzVyIE2gNE4xOyEQvF2=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd4OUCzN{c,Ojd5NkmwN\|M9N2F-
HL60	MV;GeY5kfGmxbjDhd5NigQ>?		NXPLXWdHOiCqcoO=		MVHJR\|UxKD1iMD6wN{DPxE1?	Ml;GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4M{SwN\|koRjJ6NkO0NFM6RC:jPh?=
HEK293	MUDGeY5kfGmxbjDhd5NigQ>?		MWi2JIhzew>?		MU\JR\|UxKD1iMD6wN{DPxE1?	NXuwUVJrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5NVk{PDBpPkK4PVE6OzRyPD;hQi=>
WM266.4	M4j5TGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MlPnO\|IhcHK\|		NFXLbYxKSzVyIE2gNE4xOzVizszN	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJyNki2PUc,OjJ{ME[4Olk9N2F-
GUMBUS	NVW2NnF3S3m2b4TvfIlkcXS7IHHzd4F6		MWC3NkBpenN?		MUXJR\|UxKD1iMD6wN\|Uh\|ryP	NGfKd5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{CzNVU6OCd-MkOwN\|E2QTB:L3G+
HepG2	NHzSPVREgXSxdH;4bYNqfHliYYPzZZk>		NYC5UVRHPzJiaILz		M3vofWlEPTBiPTCwMlA{PzVizszN	NFS0[IU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUWzO\|cyPid-MUm1N\|c4OTZ:L3G+
95-D	MUXDfZRwfG:6aXPpeJkh[XO\|YYm=		MXm3NkBpenN?		NXHwR2V1UUN3MDC9JFAvODN6IN88US=>	NWrmToFpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki2N\|QxOzlpPkK4OlM1ODN7PD;hQi=>
95-D	NELTOplCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M4PZVlczKGi{cx?=		M4e0[2lEPTBiPTCwMlA{QDF6IN88US=>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd4OUCzN{c,Ojd5NkmwN\|M9N2F-
SW480	MkXhR5l1d3SxeHnjbZR6KGG\|c3H5		Ml;MO\|IhcHK\|		NHG5PI1KSzVyIE2gNE4xPSEQvF2=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV\|N{exOkc,OTl3M{e3NVY9N2F-
KB	Mn;QR5l1d3SxeHnjbZR6KGG\|c3H5		NVvzU4pDPzJiaILz		MlW1TWM2OCB;IECuNFU6PSEQvF2=	NE\idXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUWzO\|cyPid-MUm1N\|c4OTZ:L3G+
SKOV3	NUWzWo9WS3m2b4TvfIlkcXS7IHHzd4F6		MofSO\|IhcHK\|		NISzcGpKSzVyIE2gNE4xPjZ6IN88US=>	M4e5elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMEe3OlgyLz5{MUC3O\|Y5OTxxYU6=
SW1990	MVXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmTVO\|IhcHK\|		Mn7LTWM2OCB;IECuNFc6ODZizszN	NVnhZ2U3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3OlkxOzNpPkK3O\|Y6ODN\|PD;hQi=>
HeLa	NFHuV\|lEgXSxdH;4bYNqfHliYYPzZZk>		NF32XYs4OiCqcoO=		MXHJR\|UxKD1iMD6wPVIh\|ryP	NYK4SIJNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1N\|c4OTZpPkG5OVM4PzF4PD;hQi=>
A549	NGnMcJJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MVm3NkBpenN?		Ml;kTWM2OCB;IECuNFkzKM7:TR?=	NEDtOZQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG5NVg2OCd-MkixPVE5PTB:L3G+
H460	M3LwN2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MmnTO\|IhcHK\|		M176eGlEPTBiPTCwMlEyPSEQvF2=	M13CdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUO3O\|E3Lz5zOUWzO\|cyPjxxYU6=
SKOV3	NXvzXW5zS3m2b4TvfIlkcXS7IHHzd4F6		MVu3NkBpenN?		M4TrSWlEPTBiPTCwMlE{KM7:TR?=	M1rqfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUO3O\|E3Lz5zOUWzO\|cyPjxxYU6=
SKOV3	NFLwWVJEgXSxdH;4bYNqfHliYYPzZZk>		MWm3NkBpenN?		NELlUoZKSzVyIE2gNE4yPTFizszN	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODF3OEG4OEc,OjBzNUixPFQ9N2F-
A549	M{HaOGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MlX1O\|IhcHK\|		NHWydIpKSzVyIE2gNE4zPTVizszN	NITkeWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUWzO\|cyPid-MUm1N\|c4OTZ:L3G+
HL60	NXHqd49YTnWwY4Tpc44h[XO\|YYm=		M{C5UFIhcHK\|		M{DW[2lEPTBiPTCwMlQ1KM7:TR?=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd4OUCzN{c,Ojd5NkmwN\|M9N2F-
HL60	MU\GeY5kfGmxbjDhd5NigQ>?		M2DIVlIhcHK\|		M13xd2lEPTBiPTCwMlQ1KM7:TR?=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ\|NECzPUc,Ojh4M{SwN\|k9N2F-
H460	M{TZfWN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1PRPFczKGi{cx?=		MYLJR\|UxKD1iMD63PEDPxE1?	M1KxOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUW4NVg1Lz5{MEG1PFE5PDxxYU6=
BGC823	MoTtR5l1d3SxeHnjbZR6KGG\|c3H5		MVi3NkBpenN?		MoDwTWM2OCB;IECuPFgh\|ryP	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTV\|N{exOkc,OTl3M{e3NVY9N2F-
MCF7	M{nyfmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NIf4fVY4OiCqcoO=		NVWxXIxqUUN3MDC9JFE5NjN5IN88US=>	NWf6RWU{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NlY3OjlpPkK5OFI3PjJ7PD;hQi=>
A549	NWfTfIVUSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NF22bJE4OiCqcoO=		NFe2d2ZKSzVyIE2gNk4yOzV5MzFOwG0>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd4OUCzN{c,Ojd5NkmwN\|M9N2F-
A549	NIL4c3BEgXSxdH;4bYNqfHliYYPzZZk>		M2fSdFczKGi{cx?=		M32xNGlEPTBiPTCyMlE1KM7:TR?=	NGrLSJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OE[zOFA{QSd-Mki2N\|QxOzl:L3G+
BGC823	MUXDfZRwfG:6aXPpeJkh[XO\|YYm=		MY[3NkBpenN?		NEjTfmlKSzVyIE2gNk45QSEQvF2=	NHPZUow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe0O\|g{Oid-MUm3OFc5OzJ:L3G+
MDA-MB-231	NFvEXJdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MXW3NkBpenN?		NF7NTmFKSzVyIE2gN{4yOjVizszN	NHv3Onk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSyOlYzQSd-Mkm0NlY3Ojl:L3G+
BCG823	MVTDfZRwfG:6aXPpeJkh[XO\|YYm=		Mk\OO\|IhcHK\|		NXTWZXUxUUN3MDC9JFMvOjlizszN	MmjkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNUixPFQoRjJyMUW4NVg1RC:jPh?=
A549	NHLBV2tCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVHOeXBtPzJiaILz		MX\JR\|UxKD1iOT6zNVgh\|ryP	NYTTUFA1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NlY3OjlpPkK5OFI3PjJ7PD;hQi=>
Calu6	M4nzOWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NWW2b5NRPzJiaILz		NFj6fFNNSzVyIE2gNE4xODZzIN88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh5NUezPUc,OjB6N{W3N\|k9N2F-
HEK293T	NEno[YhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MV[0PEBpenN?		NHvL[Y9NSzVyIE2gNE4xOTZizszN	M2DSeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7OESzNVAxLz5{OUi0N\|ExODxxYU6=
LO2	Ml3rRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NYDodHFvPDhiaILz		MWnMR\|UxKD1iMD6zPVgh\|ryP	NFXHVXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi0N\|ExOCd-Mkm4OFMyODB:L3G+
NCI-H929	NY\NeVVPS3m2b4TvfIlkcXS7IHHzd4F6		MnmwOFghcHK\|		MXTMSFUxKD1iMD6wNFY3KM7:TR?=	MmnPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|QoRjJ5OUm0O\|M1RC:jPh?=
U266	M3TXV2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MoHuOFghcHK\|		MYXMSFUxKD1iMD6wNVgh\|ryP	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOEc,Ojd7OUS3N\|Q9N2F-
LCL	MXLDfZRwfG:6aXPpeJkh[XO\|YYm=		NXvTN443PDhiaILz		M{PjO2xFPTBiPTCwMlAzKM7:TR?=	NH\oXoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{PCd-Mke5PVQ4OzR:L3G+
MDA-MB-468	M2PTSGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MnPNOFghcHK\|		MoTxUGQ2OCB;IECuNFM4KM7:TR?=	NWXPNGRKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzRpPkK3PVk1PzN2PD;hQi=>
RD-ES	MWHDfZRwfG:6aXPpeJkh[XO\|YYm=		NXrTU4k6PDhiaILz		NYL1WnNoVER3MDC9JFAvODRizszN	MoTaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|QoRjJ5OUm0O\|M1RC:jPh?=
WE68	M2j3N2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M2TjSFQ5KGi{cx?=		NVnpUm92VER3MDC9JFAvOSEQvF2=	NGHXcoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{PCd-Mke5PVQ4OzR:L3G+
IMR90	M3LVXWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MlXGOFghcHK\|		MUXMSFUxKD1iMD6xN{DPxE1?	MljPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|QoRjJ5OUm0O\|M1RC:jPh?=
KGN	MWfDfZRwfG:6aXPpeJkh[XO\|YYm=		MXe0PEBpenN?		M1rXe2xFPTBiPTCwMlE5KM7:TR?=	NYf3UllKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzRpPkK3PVk1PzN2PD;hQi=>
HNDF	NEjP[4FEgXSxdH;4bYNqfHliYYPzZZk>		MXm0PEBpenN?		NXzZOGRwVER3MDC9JFAvPDhizszN	MkX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7OUS3N\|QoRjJ5OUm0O\|M1RC:jPh?=
MCF10A	M3nEfGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MlLkOFghcHK\|		MkToUGQ2OCB;IEGuOUDPxE1?	NGXKRXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{m5OFc{PCd-Mke5PVQ4OzR:L3G+
SKOV3	NU[4Z2lxS3m2b4TvfIlkcXS7IHHzd4F6		MonaOFghcHK\|		MV7MSFUxKD1iMT62JO69VQ>?	NXK1VpV3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzRpPkK3PVk1PzN2PD;hQi=>
MCF7	NHHke41EgXSxdH;4bYNqfHliYYPzZZk>		MkjWOFghcHK\|		M3jTbmxFPTBiPTC5Mlgh\|ryP	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOEc,Ojd7OUS3N\|Q9N2F-
HL60	NW\rbHVTTnWwY4Tpc44h[XO\|YYm=	MmTRNVAxKG6P			MU\Jcohq[mm2aX;uJI9nKGOqeX3veJJ6eHOrbj3sbYtmKGGldHn2bZR6KG:oIIDyc5Rm[XOxbXWgbY4hcHWvYX6gTGw3OCClZXzsd{BifCBzMECgcm0>	NETUXZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[1OVc3Oid-MUm2OVU4PjJ:L3G+
HeLa	Ml7MSpVv[3Srb36gZZN{[Xl?	MlHHOUBvVQ>?	NUT2W4I3QCCqcoO=		M13CXGlvcGmkaYTpc44hd2ZicILveIVie2:vZTDhZ5Rqfmm2eTDpckBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjD1ZolyfWm2aX7HO\|ZXNU[OIILldI9zfGW{IHzleoVtKGG2IEWgcm0h[W[2ZYKgPEBpenNiYomgcJVkcW[ncnHz[UBie3OjeR?=	NGrpc3I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG4Olc6PCd-MkGxPFY4QTR:L3G+
HeLa	NWX3O292TnWwY4Tpc44h[XO\|YYm=	M3;BVVEhfU1?	MXy4JIhzew>?		M1HxdWlvcGmkaYTpc44hd2ZicILveIVie2:vZTDhZ5Rqfmm2eTDpckBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjD1ZolyfWm2aX7HO\|ZXNU[OIILldI9zfGW{IHzleoVtKGG2IEGgeW0h[W[2ZYKgPEBpenNiYomgcJVkcW[ncnHz[UBie3OjeR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF6Nke5OEc,OjFzOE[3PVQ9N2F-
LN229	M3u1bmZ2dmO2aX;uJIF{e2G7	MoLhNVAxKG6P	NWLNWFh3OSCqch?=		M3zzeWlvcGmkaYTpc44hd2ZiSFnGNYFteGijIHX4dJJme3Orb36gbY4hcHWvYX6gUG4zOjliY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIH;mJGhKTi1zYXzwbIEh[WOldX31cIF1cW:wIHH0JFExOCCwTTDwdoVqdmO3YnH0[YQh\m:{IEGgbJIhfW6mZYKgco9zdW:6aXGgZ49v\Gm2aX;uJIZwdGyxd3XkJIJ6KDJ2IHjyd{BqdmO3YnH0bY9vKHWwZHXyJIh6eG:6aXGgZ49v\Gm2aX;uJIJ6KFenc4Tldo4h[myxdITpcoc>	M{TXNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEOxOlM5Lz5{MUizNVY{QDxxYU6=
LN229	NVLBZnVJTnWwY4Tpc44h[XO\|YYm=	MXKyNEB2VQ>?	NEfaV2EyKGi{		Ml3aTY5pcWKrdHnvckBw\iCqeYDvfIliNWmwZIXj[YQhUEmIMXHsdIhiKGGlY4XteYxifGmxbjDpckBpfW2jbjDMUlIzQSClZXzsd{BifCB{MDD1UUBi\nSncjCxJIhzKHC{ZXnuZ5Vj[XSrb36gcYVie3W{ZXSgZYZ1\XJiMkSgbJJ{KGK7IGfld5Rmem5iYnzveEBidmGueYPpdy=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB\|Mk[zNkc,OjJyM{K2N\|I9N2F-
U1	MmfISpVv[3Srb36gZZN{[Xl?	M4fx[VExKHWP	M3HrRVI1KGi{		MU\Jcohq[mm2aX;uJI9nKE6ILXvhdJBiSi2vZXTpZZRm\CC4aYLhcEBz\XCuaXPheIlwdiCrbjDIc41wKHOjcHnlcpMhMGi3bXHuLUBWOSClZXzsd{Bqdm[nY4Tl[EB4cXSqIGi0JJRzd3CrYzDITXYyKE6OND2zJIF1KDFyIIXNJIFnfGW{IEK0JIhzKGK7IGLUMXBEWiCjbnHsfZNqeyCrbjDwdoV{\W6lZTDv[kBVVkZvYXzwbIE>	M3fkeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MkmwNFUyLz5{M{K5NFA2OTxxYU6=
Calu6	M1Hlb2Z2dmO2aX;uJIF{e2G7	NG\WUmMyOCC3TR?=	MVqxPEBpenN?		NUm2RZVUUW6qaXLpeIlwdiCxZjDIbZMufGGpZ3XkJGZz[XSjeHnuJEh2dmuwb4fuJI9zcWerbjmvWYJqeXWrdHnuJIlvfGW{YXP0bY9vKGW6cILld5Nm\CCrbjDoeY1idiCFYXz1OkBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCocnH0ZZhqdiBqMT2yNVAqKHC{ZXP1dpNweiCuZY\lcEBifCBzMDD1UUBi\nSncjCxPEBpenNiYomgW4V{fGW{bjDicI91fGmwZzDhcoFtgXOrcx?=	NYm1UFR4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NFY1QDZpPkKzOVA3PDh4PD;hQi=>
HCT116	M1zmTWZ2dmO2aX;uJIF{e2G7				NHTx[lNKdmirYnn0bY9vKG:oIIDyc5Rm[XOxbXWgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBw\iCyNUOgZpkhX2W\|dHXyckBjdG:2dHnu[{BidmGueYPpdy=>	M17oWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUS3O\|U4Lz5{M{W0O\|c2PzxxYU6=
HCT116	MXjBdI9xfG:\|aYOgZZN{[Xl?				NHe1WGdKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gVGFTWCClbHXheoFo\SCkeTDX[ZN1\XKwIHLsc5R1cW6pIHHuZYx6e2m\|	MnH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NEe3OVcoRjJ\|NUS3O\|U4RC:jPh?=
HCT116	MmPOR4VtdCCleXPs[UBie3OjeR?=		NWLvVFhCOjRiaILz		MlviR4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gTGNVOTF4IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBifCCJMj;NJJBp[XOnIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtd3diY4n0c41mfHKrYzDhcoFtgXOrcx?=	MnPmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3NEe3OVcoRjJ\|NUS3O\|U4RC:jPh?=
HEK293	NHPwcWdEgXSxdH;4bYNqfHliYYPzZZk>	NX7CUpNMOC5yMECxJJVOKHSxIEGwNEB2VQ>?	NELpeXQ1QCCqcoO=		M1zYU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhGUzJ7MzDj[YxteyCneIDy[ZN{cW6pIH31dolv\SCIQWCgZZQhOC5yMECxJJVOKHSxIEGwNEB2VSCjZoTldkA1QCCqcoOgZpkhS2WubGTpeIVzNUKudXWgZZN{[Xl?	M4\IfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUm0NlcyLz5{M{W5OFI4OTxxYU6=
A549	MXvGeY5kfGmxbjDhd5NigQ>?	MV[wMlAzPSC2bzCwMlUhfU1?	NYTocpV[OjRiaILz		M2SxN2lv\HWldHnvckBw\iClZXzsJIRm[XSqIHnuJIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJBwdHlvdXLpdZVqfGmwYYTl[EBxem:2ZXnud{BifCByLkCyOUB1dyByLkWgeW0h[W[2ZYKgNlQhcHK\|IHL5JIludXWwb3Lsc5Qh[XO\|YYm=	NXzzSlc2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW2N\|k5PjJpPkK1OlM6QDZ{PD;hQi=>
A549	NV32S2Y1TnWwY4Tpc44h[XO\|YYm=	MV2wMlAzPSC2bzCwMlUhfU1?	NWDxfYhsOjRiaILz		NH\PdlNKdmS3Y4Tpc44hd2ZiY3XscEBl\WG2aDDpckBpfW2jbjDBOVQ6KGOnbHzzJIF{e2W\|c3XkJIF{KHO2YXLpcIl7[XSrb36gc4YheDV\|IHH0JFAvODJ3IITvJFAvPSC3TTDh[pRmeiB{NDDodpMh[nliaX3teY5w[myxdDDhd5NigQ>?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTZ\|OUi2Nkc,OjV4M{m4OlI9N2F-
A549	MmjUSpVv[3Srb36gZZN{[Xl?	M3nNSlAvODJ3IITvJFAvOSC3TR?=	NXn4N2gyOjRiaILz		MlLCTY5lfWO2aX;uJI9nKGOnbHyg[IVifGhiaX6gbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[gUo95[SCjdDCwMlAzPSC2bzCwMlEhfU1iYX\0[ZIhOjRiaILzJIJ6KGmvbYXuc4Jtd3RiYYPzZZk>	NGf5OmE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[zPVg3Oid-MkW2N\|k5PjJ:L3G+
AMO1	MnvrRY51cXS3bX;yJIF{e2G7	NYK3OmtZOSCvZz;r[y=>			NWPBcVd[SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRW1QOSClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueYRmKFOFSVSgZoVq\2VibX;1d4Uh[XO\|ZYPz[YQh[XNidIXtc5Ih\3Kxd4ToJIlvcGmkaYTpc44h[XRiMTDt[{9s\yxiaY[gZYRucW6rc4TldoVlKHS5aXPlJJBmeiC5ZXXr	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV4NU[2Okc,OjZ3NkW2OlY9N2F-
MCF7	MmTGSpVv[3Srb36gZZN{[Xl?	MWKzOUBvVQ>?	MknMOEBpenN?		MmHwTY5pcWKrdHnvckBw\iB{NmOgdJJwfGWjc3;t[UBqdiCqdX3hckBOS0Z5IHPlcIx{KGG\|c3Xzd4VlKGG\|IHHjZ5VufWyjdHnvckBw\iCqaXfoJI1wdGWldXzhdkB4\WmpaISgdI9tgXWkaYH1bZRqdi2lb37qeYdifGWmIIDyc5RmcW6\|IHH0JFM2KG6PIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzl7NEezOEc,Ojd7OUS3N\|Q9N2F-
MDA-MB-468	Mn7jSpVv[3Srb36gZZN{[Xl?	MVqzOUBvVQ>?	MWG0JIhzew>?		M4T1dGlvcGmkaYTpc44hd2ZiMk\TJJBzd3SnYYPvcYUhcW5iaIXtZY4hVUSDLV3CMVQ3QCClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4YhcGmpaDDtc4xm[3WuYYKge4Vq\2i2IIDvcJl2[mmzdXn0bY4u[2:waoXnZZRm\CCycn;0[YlveyCjdDCzOUBvVSCjZoTldkA1KGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	NWC0SZI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5PVQ4OzRpPkK3PVk1PzN2PD;hQi=>
MDA-MB-231	M3\CTGZ2dmO2aX;uJIF{e2G7	NFPKS\|YyKHWP			NWXxe3o6UW6qaXLpeIlwdiCxZjD0dplxe2mwIHzpb4Uh[WO2aY\peJkhd2ZiMk\TJJBzd3SnYYPvcYUh\GW{aY\l[EBnem:vIHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XRiMTD1US=>	M2izcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkmxN\|Q1Lz5{OEK5NVM1PDxxYU6=
MDA-MB-231	NEjySlJHfW6ldHnvckBie3OjeR?=	MXixJJVO			MY\Jcohq[mm2aX;uJI9nKGOjc4Dhd4UhdGmtZTDhZ5Rqfmm2eTDv[kAzPlNicILveIVie2:vZTDk[ZJqfmWmIH\yc40hcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDheEAyKHWP	NELJV3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK5NVM1PCd-MkiyPVE{PDR:L3G+
MDA-MB-231	NHvSUYpHfW6ldHnvckBie3OjeR?=	NIPwS5oyKHWP			NYnzPWJGUW6qaXLpeIlwdiCxZjDjbJlud3S{eYDzbY4hdGmtZTDhZ5Rqfmm2eTDv[kAzPlNicILveIVie2:vZTDk[ZJqfmWmIH\yc40hcHWvYX6gUWRCNU2ELUKzNUBk\WyuczDheEAyKHWP	MlTiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OUGzOFQoRjJ6MkmxN\|Q1RC:jPh?=
SK-N-SH	MlS3R5l1d3SxeHnjbZR6KGG\|c3H5	NXv0[lRxOC5zIITvJFEhfU1?	NYjHXnZIOjRiaILz		Moi1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2suVi2VSDDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZZQhOC5zIITvJFEhfU1iYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigQ>?	Mni1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl{NkmyOVUoRjJ7Mk[5NlU2RC:jPh?=
MYCN2	MXfDfZRwfG:6aXPpeJkh[XO\|YYm=	NXjIZ4ZEOC5zIITvJFEhfU1?	NUH2WVJzOjRiaILz		MmjZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXlEVjJiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHH0JFAvOSC2bzCxJJVOKGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZk>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTJ4OUK1OUc,Ojl{NkmyOVU9N2F-
U266	NXvVPIVFSXCxcITvd4l{KGG\|c3H5	MoPrNk42KG6P	M3HiOlI1KGi{cx?=		MWTJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKFV{Nk[gZ4VtdHNiYYSgNk42KG6PIHHmeIVzKDJ2IHjyd{BjgSCDbn7lfIlvKFZxcILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\yCkYYPl[EBndG:5IHP5eI9u\XS{eR?=	NGf4XXI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUOwOFI5PCd-MkmzNFQzQDR:L3G+
RPMI8226	M3LkNmFxd3C2b4Ppd{Bie3OjeR?=	Mlq1Nk42KG6P	M2T4bVI1KGi{cx?=		M4rpSGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iUmDNTVgzOjZiY3XscJMh[XRiMj61JI5OKGGodHXyJFI1KGi{czDifUBCdm6neHnuJHYweHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDmcI94KGO7dH;t[ZRzgQ>?	M{DH[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7M{C0Nlg1Lz5{OUOwOFI5PDxxYU6=
NCI-H929	NGO0d2JCeG:ydH;zbZMh[XO\|YYm=	NGmzbYEzNjVibl2=	NGry[XEzPCCqcoO=		M4i5[Wlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTlPJMWg6OjliY3XscJMh[XRiMj61JI5OKGGodHXyJFI1KGi{czDifUBCdm6neHnuJHYweHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{Bj[XOnZDDmcI94KGO7dH;t[ZRzgQ>?	NEnWXW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUOwOFI5PCd-MkmzNFQzQDR:L3G+
TC32	M4HkZZFJXFNiYYPzZZk>				NIi5OohyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiVFOzNkBk\Wyucx?=	NYHiPVM6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS	MkXldWhVWyCjc4PhfS=>				MlfwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?=	M{TFW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673	MVLxTHRUKGG\|c3H5				M3zGeJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	NV[2PVM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY	MkHMdWhVWyCjc4PhfS=>				M1nENpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy\|	NIHkZ4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	NXfRcJFSeUiWUzDhd5NigQ>?				NWLMW3AzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	M4DRe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	MYDxTHRUKGG\|c3H5				NUjJdpVreUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	M4OzPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	NYPxNG97eUiWUzDhd5NigQ>?				NXnmS2RWeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	NVfmfWFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	MUTxTHRUKGG\|c3H5				NHnL[mpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	NFPyVlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	MXTxTHRUKGG\|c3H5				MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	MnzTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	M{PjRpFJXFNiYYPzZZk>				M1rRTZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	NYjX[G5VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	NHKyT4hyUFSVIHHzd4F6				NUXkZ4xieUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	M1HFW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	MV;xTHRUKGG\|c3H5				Mn;WdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	NGTueHc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	MoTzdWhVWyCjc4PhfS=>				NWr2WW94eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	NIm5fY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
fibroblast	NIjjcI5yUFSVIHHzd4F6				MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5Ih[2:wdILvcEBJcCC5aXzkJJR6eGViZnnido9jdGG\|dDDj[Yxtew>?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	NEHJNJNyUFSVIHHzd4F6				NVXXTZV2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	M2HDRVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
DAOY	MX\xTHRUKGG\|c3H5				MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDERW9[KGOnbHzz	NIL3VZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	MUTxTHRUKGG\|c3H5				M2XwTpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DNUWEY{GgZ4VtdHN?	NIPjPYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	MXjxTHRUKGG\|c3H5				MVLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	MnzwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	MWXxTHRUKGG\|c3H5				NGTYdo5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy\|	MnfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	M1i4OpFJXFNiYYPzZZk>				M2TIb5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEOwJINmdGy\|	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	MXXxTHRUKGG\|c3H5				MUTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=>	M1PCb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	NFTQcVNyUFSVIHHzd4F6				M1vwN5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTN5IHPlcIx{	NE\wVo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	MoDxdWhVWyCjc4PhfS=>				MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	NXvmTotDeUiWUzDhd5NigQ>?				M1[5cZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJM>	M3:yNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
fibroblast	M{\NcpFJXFNiYYPzZZk>				M3jTfZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJINwdnS{b3ygTIghf2muZDD0fZBmKG[rYoLvZoxie3RiY3XscJM>	NWLRPGN7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS	NEKxXWNyUFSVIHHzd4F6				NITOO3ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBWNTJiT2OgZ4VtdHN?	NFPHV\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NGDHNWtyUFSVIHHzd4F6				MoP1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgU2hUNTVyIHPlcIx{	M4THdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	NEHwemNyUFSVIHHzd4F6				MmTEdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBUUy2QLWPIJINmdGy\|	NYjJbJI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	NVfXdIdseUiWUzDhd5NigQ>?				MkHTdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=>	M1jYflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MYDxTHRUKGG\|c3H5				MVjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSSEBk\Wyucx?=	MkWyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Daoy	MoDXdWhVWyCjc4PhfS=>				NWTkS5lWeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCGYX;5JINmdGy\|	M3nrfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	NYHJV2t7eUiWUzDhd5NigQ>?				MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBQenSqb3fvcoFtKDOGIHPhd5Bie2Vic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	NV2yWW9VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	M1v6bZFJXFNiYYPzZZk>				M3zxV5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1Sgeoli[mmuaYT5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	Ml\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	NUPzNmI1eUiWUzDhd5NigQ>?				MmrJdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	MnjSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MonJdWhVWyCjc4PhfS=>				MVrxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NF[0bXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	MX3xTHRUKGG\|c3H5				NIPoOppyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	MV3xTHRUKGG\|c3H5				MoHMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ\|Eh[2WubIO=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	NITZc5pyUFSVIHHzd4F6				M4DLZpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	NWniSIlRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	MVfxTHRUKGG\|c3H5				MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	M{HIcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	MWjxTHRUKGG\|c3H5				M{S4XJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DOTZ2MzDj[Yxtew>?	NF\vcVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NUTmT\|N4eUiWUzDhd5NigQ>?				M3j0TpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vTVOgZ4VtdHN?	NFXORW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	MWTxTHRUKGG\|c3H5				MmG2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2ouT0KPMjDj[Yxtew>?	NVjMTVJRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	NILZWY1yUFSVIHHzd4F6				NV;HfFBOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXEN\|MjDj[Yxtew>?	MlTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	NXXYVWN{eUiWUzDhd5NigQ>?				MkThdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVogyQCClZXzsdy=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	MV\xTHRUKGG\|c3H5				NGTzOmlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBU[W:\|LUKgZ4VtdHN?	NFThdYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NGe5RZZyUFSVIHHzd4F6				NYi5TnNOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	MnLWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	MW\xTHRUKGG\|c3H5				MWXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJHJFKGOnbHzz	MmD2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
HL60	M4n0dmZ2dmO2aX;uJIF{e2G7	M33RN\|EhfG9iMUCwJI5O	NXTJPGg5OjRiaILz		MXrJcohq[mm2aX;uJI9nKHC{b4TlZZNwdWViaX6gbJVu[W5iSFy2NEBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiClbHXheoVlKFCDUmCg[ZhxemW\|c3nvckBifCBzIITvJFExOCCwTTDh[pRmeiB{NDDodpMh[nliaX3teY5w[myxdDDhd5NigQ>?	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
SUP-B15	MUDGeY5kfGmxbjDhd5NigQ>?	NGrPemEyKHSxIEGwNEBvVQ>?	NXvmXHdUOjRiaILz		M3;LO2lvcGmkaYTpc44hd2ZicILveIVie2:vZTDpckBqdWG2aX7pZk1z\XOrc4ThcpQhcHWvYX6gV3VRNUJzNTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBkdGWjdnXkJHBCWlBiZYjwdoV{e2mxbjDheEAyKHSxIEGwNEBvVSCjZoTldkAzPCCqcoOgZpkhcW2vdX7vZoxwfCCjc4PhfS=>	NUjpPYRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOlU5QTJpPkOwN\|Y2QDl{PD;hQi=>
SEM	NETiZnZHfW6ldHnvckBie3OjeR?=	MXixJJRwKDFyMDDuUS=>	MlfTNlQhcHK\|		M4XXcWlvcGmkaYTpc44hd2ZicILveIVie2:vZTDpckBpfW2jbjDTSW0h[2WubIOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iY3zlZZZm\CCSQWLQJIV5eHKnc4Ppc44h[XRiMTD0c{AyODBibl2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4SgZZN{[Xl?	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODN4NUi5Nkc,OzB\|NkW4PVI9N2F-
SEM	MUnGeY5kfGmxbjDhd5NigQ>?	NGTjXXQyOCCwTR?=	NWmzflh4OThiaILz		NFLJbXJKdmirYnn0bY9vKG:oIIDyc5Rm[XOxbXWgbY4hcHWvYX6gV2VOKGOnbHzzJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHHn[5Jme2:vZTDhZ4N2dXWuYYTpc44h[XRiMUCgcm0h[W[2ZYKgNVghcHK\|IHL5JIJ6KE[DQ2OgZY5idHm\|aYO=	MnriQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB\|NkW4PVIoRjNyM{[1PFkzRC:jPh?=
SEM	Mn61SpVv[3Srb36gZZN{[Xl?	MnzrNVAhdk1?	NI\1V2syQCCqcoO=		MXXJcohq[mm2aX;uJI9nKHC{b4TlZZNwdWViaX6gbJVu[W5iU1XNJINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKGGpZ4Lld49u\SCjY3P1cZVt[XSrb36gZZQhOTBibl2gZYZ1\XJiMUigbJJ{KGK7IH\seY9z\XOlZX7j[UBucWO{b4Pjc5Bq[yCvZYToc4Q>	NXjxO3J{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CzOlU5QTJpPkOwN\|Y2QDl{PD;hQi=>
HepG2	NFvTW3JE\WyuII\pZYJqdGm2eTDhd5NigQ>?				M{HyNGhmeEd{IHPlcIx{KH[rYXLpcIl1gSCzSGTTJIZweiCcaXvhJJZqenW\|IHnubIljcXSxcoO=	MoHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzN{Mkm1OFUoRjN\|MkK5OVQ2RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	phospho-PERK / ATF-4; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against phospho-PERK, ATF-4. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. GRP-78 / GADD-34; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were treated with PS-341 for the indicated time periods and concentrations. Whole-cell extracts were prepared, and 50-μg aliquots of proteins were probed with polyclonal antibodies against GRP-78, and GADD-34. For loading control, the membranes were stripped and reprobed with monoclonal antibodies against α-tubulin. pro-caspase-12 / pro-caspase-3; PubMed: 15509775 Mol Cell Biol MEFs were treated with PS-341 for the indicated time periods, and the whole-cell extracts were prepared. Fifty-microgram aliquots of proteins were probed with polyclonal antibodies against caspase 12 and caspase 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. pro-caspase-9; PubMed: 15509775 Mol Cell Biol UMSCC-23 cells were pretreated with or without Tiron for 30 min and then treated with PS-341 for the indicated time periods. The whole-cell proteins were probed with polyclonal antibodies against caspases 9 and 3. For loading control, the membrane was stripped and reprobed with monoclonal antibodies against α-tubulin. p-IκBα / IκBα; PubMed: 20335171 J Biol Chem PS-341 induces IκBα degradation in human lung cancer cells. The given cells lines were treated with the indicated concentrations of PS-341 for 8 h (C). After treatment, the cells were then subjected to preparation of whole-cell protein lysates and subsequent Western blot analysis. COX-2 / cIAP2; PubMed: 24085292 J Biol Chem NCI-H157 cells were incubated with PS-341 (50 nM) or MG132 (20 μM) for the indicated times. Total cellular extracts were subjected to Western blot analysis for COX-2, cIAP2 and actin.	15509775 20335171 24085292
Immunofluorescence	Vimentin; PubMed: 19010849 Clin Cancer Res ES-2 ovarian cancer cells were incubated with 5nM PS-341, 10 μM NK84 or the combination of both for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective). Ubiquitin; PubMed: 19010849 Clin Cancer Res IOSE-29 cells were incubated with 20nM PS-341 for 24 hours before fixation and immuno-fluorescent staining of DNA (blue), ubiquitin (green) and vimentin (red) and imaging (X60 objective).	19010849
Growth inhibition assay	Cell viability ; PubMed: 20571067 Mol Cancer Ther A, TSA enhanced the cell death induced by PS-341 in UMSCC1 cells. Cell viability was determined by the trypan blue exclusion assay. The assays were performed with triplicate samples, and the results are representative of three independent experiments (P < 0.01). Error bars depict standard deviation. B, C and D, TSA enhanced PS-341-induced cell death in UMSCC23 (B), UMSCC9 (C), and FaDu (D). P < 0.01.	20571067
ELISA	IL-8; PubMed: 24085292 J Biol Chem NCI-H157 cells were treated with PS-341 (10–100 nm) or TNF-α (10 ng/ml) as a positive control for 24 h. IL-8 concentrations in media were determined by ELISA. Data represent the mean ± S.D. of triplicates. **, p < 0.05 versus control cells. Results are representative of three separate experiments.	24085292

In vivo

The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. ^[2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. ^[3]

Protocol

Kinase Assay: ^[4]	- Collapse Kinetic Methods: In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λ_ex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research: ^[5]	- Collapse Cell lines: Human multiple myeloma cells line U266 Concentrations: ~10 μM Incubation Time: 2 days Method: The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: Human plasmacytoma xenografts RPMI 8226 Dosages: 1 mg/kg Administration: i.v. twice weekly for 4 weeks, then once weekly (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	76 mg/mL (197.79 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Bortezomib (PS-341) SDF

Molecular Weight	384.24
Formula	C₁₉H₂₅BN₄O₄
CAS No.	179324-69-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	LDP-341, MLM341, NSC 681239
Smiles	B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04656951	Not yet recruiting	Drug: Daratumumab	Multiple Myeloma	University of Cologne\|Janssen-Cilag G.m.b.H	January 2021	Phase 2
NCT04570631	Recruiting	Drug: Eftozanermin alfa\|Drug: Bortezomib\|Drug: Dexamethasone	Multiple Myeloma	AbbVie	November 5 2020	Phase 1
NCT03993262	Recruiting	Drug: Bortezomib\|Drug: Placebo	Autoimmune Encephalitis	Jena University Hospital	May 13 2020	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?
Answer:
S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Pan Proteasome Inhibitor

Ixazomib (MLN2238) : β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.
FDA-approved Proteasome Inhibitor

Carfilzomib (PR-171) : Approved by FDA for multiple myeloma.
Newest Proteasome Inhibitor

Oprozomib (ONX 0912) : Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.
Classic Proteasome Inhibitor

ONX-0914 (PR-957) : Selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

Related Proteasome Products

VR23 ^New

VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.
Calpeptin ^New

Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively. Calpeptin attenuates apoptosis and intracellular inflammatory changes in muscle cells.
Marimastat (BB-2516) ^New

Marimastat (BB-2516, TA2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.
MG-132

MG132 (Z-Leu-Leu-Leu-al) is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 μM and 1.2 μM for the inhibition of proteasome and calpain, respectively. MG132 activates autophagy and induces apoptosis in tumor cells.
Carfilzomib (PR-171)

Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. Carfilzomib activates prosurvival autophagy and induces cell apoptosis.
Ixazomib (MLN2238)

Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and K_i of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Ixazomib (MLN2238) induces autophagy. Phase 3.

Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.
ONX-0914 (PR-957)

ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).
Ixazomib Citrate (MLN9708)

Ixazomib Citrate (MLN9708) immediately hydrolyzed to Ixazomib (MLN2238), the biologically active form, on exposure to aqueous solutions or plasma. Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/K_i of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Ixazomib (MLN2238) induces autophagy. Phase 3.

Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.
Celastrol

Celastrol (Tripterine) is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM. Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway. Celastrol inhibits dopaminergic neuronal death of Parkinson's disease through activating mitophagy.

Features:A potent antioxidant and anti-inflammatory drug.
Oprozomib (ONX 0912)

Oprozomib (ONX 0912, PR-047) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Choose Your Country or Region

By Signaling Pathways

By product type

Bortezomib (PS-341)